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Abstract 
Amyotrophic Lateral Sclerosis (ALS) is an adult-onset progressive 
neurodegenerative disease that causes degeneration in both upper and lower 
motor neurons. ALS progresses relentlessly after the onset of the disease, with 
most patients die within 3-5 years of diagnosis, largely due to respiratory failure. 
Since SOD1 became the first gene whose mutations were associated with ALS in 
1993, more than 17 ALS causative genes have been identified. Among them, TAR 
DNA-binding protein (TARDBP) lies in the central of ALS pathology mechanism 
study, because TDP43 proteinopathy is observed not only in familial ALS cases 
carrying TARDBP mutations, but also in most of the sporadic ALS cases, which 
account for 90% of the whole ALS population. Several TDP43 overexpression 
mouse models have been successfully generated to study the gain-of-toxicity 
mechanism of TDP43 in ALS development, while the investigation of loss-of-
function mechanism which could also contribute to ALS still awaits a proper mouse 
model. The major difficulty in generating TARDBP knock out mouse model lies in 
the fact that TARDBP is a development essential gene and complete depletion of 
TDP43 function causes embryonic lethality.  
In chapter I, I reviewed the recent advances in ALS study. Emphasis was 
given to ALS mouse models, especially TARDBP ALS mouse model.  
In Chapter II, I made a Tet-responsive construct that contains mCherry, a 
fluorescent protein, as an indicator for the expression of the artificial miRNA 
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(amiTDP) residing in the 3’UTR of mCherry and targeting TARDBP. The construct 
was tested in NSC34 cells and TRE-mCherry-amiTDP43 transgenic mouse was 
generated with this construct. Crossing TRE-mCherry-amiTDP43 mouse with 
mPrp-tTA mouse, mCherry expression was successfully induced in mouse 
forebrain and cerebellum, but not in other tissues including spinal cord. By 
quantitative real-time PCR, amiTDP43 expression was confirmed to be coupled 
with mCherry expression. Fluorescent immunostaining revealed that mCherry was 
expressed in neurons, but not in astrocytes or microglia cells, and that in mCherry 
positive cells, TDP43 was significantly knocked down. Results from Nissl staining 
and GFAP immunostaining suggested that decrease of TDP43 in forebrain neuron 
only was not sufficient to cause neurodegeneration and neuron loss.  
In chapter III, I investigated the function of Armadillo Containing Protein 4 
(ARMC4), which was originally considered ALS causative gene. Our study of the 
function of CG5155, the possible homolog of ARMC4 in Drosophila, indicated that 
CG5155 is a male fertility gene that is involved in spermatogenesis. Therefore, we 
have named this gene Gudu. The transcript of Gudu is highly enriched in adult 
testes. Knockdown of Gudu by a ubiquitous driver leads to defects in the formation 
of the individualization complex that is required for spermatid maturation, thereby 
impairing spermatogenesis. Furthermore, testis-specific knockdown of Gudu by 
crossing the RNAi lines with Bam-Gal4 driver is sufficient to cause the infertility 
and defective spermatogenesis. Since Gudu is highly homologous to vertebrate 
ARMC4, also an Armadillo-repeat-containing protein enriched in testes, our results 
xii 
 
suggest that Gudu and ARMC4 is a subfamily of Armadillo-repeat containing 
proteins with an evolutionarily conserved function in spermatogenesis. 
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1.1 Abstract 
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease 
in the United States, is the most common motor neuron disease. Affecting both 
upper (UMN) and lower motor (LMN) neurons in the brain and spinal cord, ALS 
causes progressive neuron degeneration, which leads to a deterioration of 
neuromuscular function, skeletal muscle weakness, atrophy, fasciculations and 
spasticity. The onset of ALS symptom is usually in the 5th or 6th decade of life, with 
juvenile cases very rare to be seen. However, the progression of ALS is so rapid 
that most patients die within 3-5 years of diagnosis, mostly due to respiratory 
failure.  Since the symptom first clearly described by the French neurologist 
Charcot over 140 years ago, the causes of ALS remains largely unknown until 
Cu/Zn superoxide dismutase 1 (SOD1) became the first gene reported to be 
associated with the disease in 1993. Traditionally, ALS is classified into two 
categories: familial ALS (FALS) and sporadic ALS (SALS). Clinically, FALS and 
SALS are very similar. Their difference is that FALS patients have affected 
relatives. Only 10% of ALS cases are familial (FALS), and the vast majority of ALS 
cases are sporadic (SALS). During the last two decades, a lot of efforts have been 
put to look for new causative genes and risk factors of ALS. The findings that two 
RNA binding proteins, TDP43 and FUS, are related to ALS, changed the traditional 
view towards the disease. Researchers started to study ALS as a RNA disease, 
instead of merely an abnormality at protein level. Each of these causative gene 
accounts for a small proportion of familial ALS cases. For example, SOD1 is 
3 
 
responsible for 20% of FALS, and TARDBP accounts for around 5% of FALS. The 
real breakthrough came in the fall of 2011, when the abnormal expansion of the 
hexanucleotide sequence in C9ORF72 was found in about 40% of FALS and about 
7% SALS patients.  Several strategies have been utilized to make ALS mouse 
models, and these animal models greatly facilitate our understanding of the 
mechanism of ALS.  
1.2 Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis is an adult-onset neurodegenerative disease 
that affects both upper motor neurons and lower motor neurons. Patients with ALS 
will show muscle weakness, fasciculation and spasticity, and finally paralysis. Most 
of the patients die within 3-5 years of diagnosis, largely due to respiratory failure.  
The first cases of ALS were described by Aran  (1) and Cruveilhier (2). The clear 
definition and identification of ALS was done by the French neurologist Charcot in 
1869 (3). However, Charcot claimed that ALS was never inheritable. The whole 
world started to recognize ALS as an inheritable disease in the 1950s, when 
Kurland and Mulder found that 10% of the 58 ALS patients they studied had familial 
ALS (4, 5).  
Nowadays, it’s widely accepted that 10% of ALS patients are familial (FALS), 
with the vast majority classified as sporadic ALS (SALS). FALS and SALS share 
similar clinical symptoms. These clinical presentations subdivide ALS cases into 
bulbar-onset or spinal-onset disease. Clinical neurologists today still rely on those 
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presentations to diagnose ALS. Several diagnosis criteria have been developed, 
with Awaji-Shima criteria being the most recent iteration (6). The most criticism 
those criteria face is that they assume ALS is a homogeneous motor system 
degeneration, but in fact, ALS is clinically heterogeneous even among family 
members carrying the same gene mutations. A lot of factors can partially explain 
this heterogeneity, such as the different level at which UMNs and LMNs are 
affected, different body regions where the onset occurs, and various cognitive as 
well as behavioral disturbances (7) 
Until now, almost all the available population-based epidemiological studies 
of ALS are conducted in European-derived populations, and the results are 
relatively consistent. The incidence of ALS in European-derived populations is 2-
3 people per year per 100,000 of the general population older than 15 years (8). 
ALS is slightly more frequently seen in men than in women. The higher rate in men 
is attributed to the increased frequency of spinal –onset ALS in men. ALS rate in 
populations other than European-derived population is less studied. But the 
findings that in Guam and on the Kii Peninsula of Japan, ALS occurs in higher 
frequencies, together with dietary habits of the local populations, supported the 
idea that environment plays a role in development of ALS (9). Besides the 
environmental factors mentioned above, there are other environmental risk factors 
that contribute to ALS development, such as exercise, football play, smoking, 
heavy metals, pesticides and chemicals, armed services and deployment, electric 
shock, geographical clustering, and cyanotoxins (10).  
5 
 
There is no cure for ALS yet, and Riluzole, which holds anti-glutamatergic 
properties that might reduce exitotoxicity in ALS, is the only drug in the market to 
treat ALS. Riluzole showed modest effect (3-6 months) on reducing mortality in 
two trials. However, taking Riluzole might cause some side effects, like diarrhea, 
dizziness, fatigue, nausea, and somnolence. Currently, more than half of patients 
in the U.S take Riluzole (11).  
1.3 Causative genes and related pathogenesis  
Within the whole century after Charcot described and defined ALS, there 
was no etiology found to account for the disease. The advance in genetics and 
sequencing technology in recent two decades greatly accelerate the process of 
discovering novel genes involved in ALS development. Mutations in at least 17 
(Table 1.1) known causative genes are responsible for around 70% of all FALS 
and the list is still lengthening (12, 13). Among all the causative genes for ALS, 
four of them catch most scientific attention: Cu/Zn superoxide dismutase 1 (SOD1), 
transactive response DNA-binding protein of 43 kD (TARDBP), fused in sarcoma 
(FUS) and C9ORF72. Other less prevalent ALS related genes include 
profilin1(PFN1), angiogenin (ANG), ubiquilin 2 (UBQLN2), ataxin 2 (ATXN2), 
vesicle-associated membrane protein-associated protein B and C (VAPB), and 
spastic paraplegia 11 (SPG11) (14-18).  
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Gene 
symbol Gene name Chromosome 
SOD1 Superoxide dismutase 1 21q22.11 
ALS2 Amyotrophic lateral sclerosis 2 2q33.2 
SETX Senataxin 9q34.13 
SPAST Spastin 2p24 
FUS Fused in sarcoma 16p11.2 
VAPB VAMP(vesicel-associated membraine protein)-
associated protein B and C 
20q13.33 
ANG Angiogenin 14q11.1 
TARDBP TAR DNA-binding protein 1p36.22 
OPTN Optineurin 10p13 
VCP Valosin-containing protein 9p13 
UBQLN2 Ubiquilin 2 Xp11.21 
PFN1 Profilin 1 17p13.3 
TAF15 TATA box binding protein (TBP)-associated factor 
15 
17q11.1-
q11.2 
SPG11 Spastic paraplegia 11 15q14 
C9orf72 Chromosome 9 open reading frame 72 9p21.2 
Table 1.1 Genes associated with ALS 
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1.3.1 Mis-folded SOD1 and ALS 
Mutations in Cu/Zn superoxide dismutase 1 (SOD1) account for 15%-20% 
of familial ALS cases (16). Composed of 153 amino acids, SOD1 is an enzyme 
involved in free radical scavenging. Currently, more than 160 pathogenic mutations 
have been identified in SOD1, and most of the mutations are inherited in an 
autosomal dominant manner.  The mutations affect five exons and some introns 
of the gene (19). 
Aggregation of mutant proteins is a hallmark of neurodegenerative disease, 
including ALS. Mutant SOD1 is prone to mis-folding and should be cleared out by 
one of the cellular degradation systems. However, the mis-folded SOD1 not only 
escape the degradation regulation in the cell, but also impairs the cellular 
degradation system (20, 21). Mutant SOD1 thus form aggregates and leads to a 
stress response.  Evidence shows that mutant SOD1 initiates ALS in motor 
neurons, but mutant SOD1 in astrocytes and microglia can accelerate disease 
progression (22, 23). SOD1 mutations have been introduced to mouse models and 
those mouse models have been used and are still the most widely used and 
reliable model for novel drug screening and disease physiology study.  
1.3.2 Abnormal RNA metabolism and ALS 
It is the discovery of ALS related mutations in TARDBP that changed the 
theme of ALS disease research. TARDBP encodes TDP43, a RNA/DNA binding 
protein, which is part of the family of heterogenous ribonucleoproteins and 
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normally resides in the nucleus (17, 24). TDP43 is an important protein involved in 
transcription, RNA splicing and transport (25-27) . Nearly 50 mutations have been 
found, and most of the mutations are in the C-terminal glycine-rich domain of 
TDP43. These mutations account for 5% of FALS. Wild type TDP43 shuttles 
between nucleus and cytoplasm, but the mutant TDP43 is retained in the 
cytoplasm, leaving the nucleus depleted of functional TDP43 (28, 29). In the brain, 
the cytoplasmic TDP43 is usually hyperphosphorylated, ubiquitylated and 
processed into smaller fragments (30). What is the implication of these secondary 
modification of TDP43 is still unknown. It is hypothesized that the pathogenesis of 
TDP43 is a two-step process. The first step is the clearing of TDP43 from the 
nucleus and the second step is the cytoplasmic aggregation of TDP43 (31). It’s 
striking that in most ALS patients, including SALS, TDP43 inclusion is observed 
(30). This hypothesis brings in the long-time debate: what mechanism can explain 
the pathogenicity of TDP43, gain-of-function or loss-of-function? Until now, there’s 
no definite answer to this question. It’s highly possible that both mechanism play 
a role. 
  FUS is also a DNA and RNA binding protein, and belongs to FET protein 
family, which contains TAF15 (TATA-binding protein associated factor 15) and 
EWSR (Ewing sarcoma breakpoint region 1) as well (32). Of the 50 ALS 
related mutations found in FUS, all but one are inherited dominantly (13, 33). 
Mutations in FUS account for around 5% of FALS and a very small proportion 
(<1%) of SALS (18, 33). 
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FUS share lots of similarities with TDP43. First of all, TDP43 and FUS are 
both RNA binding proteins that are important for RNA metabolisms. They contain 
RNA recognition motifs and bind to more than 6,000 mRNA and 5,500 mRNA 
respectively (34, 35). It's been reported that mutations in TDP43 and FUS led to 
changes in production of large amount of mRNAs. Secondly, FUS and TDP43 both 
localize mainly in the nucleus, although they can shuttle between the nucleus and 
the cytoplasm. Notably most mutations in FUS cause defects in transportin-
mediated nuclear import and leave FUS in the cytoplasm (36-38). Cytoplasmic 
TDP43 and FUS are recruited to stress granules where they can undergo 
secondary modifications and form inclusions. So it has been debated for a long 
time which mechanism accounts for the development of ALS by TDP43 and FUS 
mutations. Is it gain-of-function or loss-of-function or both? Thirdly, both TDP43 
and FUS contain prion-like domains which can act as a template to attract native 
proteins and include them into the aggregates (39-41). It was the findings of ALS 
related mutations in TDP43 and FUS that switch the view of the whole ALS 
research field from a proteocentric disease to RNA related disease. However, 
TDP43 and FUS never co-localize in cytoplasmic aggregates, indicating that 
mutations in those two genes probably cause ALS through quite different pathways 
(34, 42). 
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1.3.3 C9ORF72 links ALS with FTLD 
Chromosome 9 Open Reading Frame 72 (C9ORF72) was thought to be 
linked to ALS after the nucleotide repeat expansion mutations were found to be 
ALS related in the autumn of 2011 (43-45). In normal people, the hexanucleotide 
GGGGCC that is located between two transcription initiation sites of C9ORF72 
repeats usually for 2-5 times, and never exceeds 30 times . But in ALS patients, 
the expansion of this hexanucleotide can go as many as several hundred even 
thousands times. The significance of the discovery that mutations in C9ORF72 are 
linked to ALS falls into two folds. For one thing, C9ORF72 mutations account for 
about 40% of FALS and 7% of SALS (46). For another, the same mutations are 
found in FTLD (frontal temporal lobar dementia, another neurodegenerative 
disease) patients without ALS (25% familial FTLD patients and 6% sporadic FTLD 
patients). This finding further links ALS and FTLD at the molecular level (43-46). 
The normal function of C9ORF72 and how the abnormal expansion of 
GGGGCC hexanucleotide could lead to ALS are still largely unknown. 
1.4 Mouse models of ALS 
In the last two decades, the advances in genetics facilitate the discovery of 
more than 17 genes in which mutations can cause ALS (12, 13). To understand 
the pathophysiology of ALS and to assist in the development of therapeutic 
strategies, researchers have generated several mouse models. In this part, SOD1 
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mouse model, the earliest developed ALS mouse model, and various TARDBP 
ALS mouse models are discussed.   
1.4.1 SOD1 mouse models of ALS 
As the first gene whose mutations were found in FALS in 1993 (16), SOD1 
has been the focus to generate mouse models until the recent discoveries of the 
involvement of RNA binding proteins, such as TDP43 (30) and FUS (18), in the 
development of ALS. SOD1 is an enzyme that can clear out cytoplasmic reactive 
oxygen species, thus preventing oxidative stress (16). Based on the association of 
reactive oxygen species with neurodegenerative diseases, it was natural for 
researchers to hypothesize that loss of dismutase activity in mutant SOD1 was the 
cause of ALS (16). However, in Sod1 knock-out mice (Sod1-/-), neuronal loss was 
not observed, and motor dysfunction was not seen up to 6 months. This result 
ruled out the possibility that the loss of dismutase activity was the ultimate cause 
of ALS (47). In the other direction, shortly after ALS related mutations in SOD1 
were identified, a transgenic mouse model (SOD1G93A), which became the most 
widely used ALS mouse model, was generated. This mouse model expresses 20-
24 copies of the human SOD1 protein containing G93A mutation. And the mutant 
transgene is under the control of human SOD1 promoter (48). This G93A SOD1 
overexpression mouse model successfully recapitulate many features of ALS, 
such as progressive neuromuscular dysfunction, neuronal loss, gliosis, and 
mitochondria dysfunction. Later on, about 20 other mutant SOD1 transgenic mice 
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were developed (48-57). Our basic understanding about pathophysiology of ALS 
mostly come from the in depth study of those mutant SOD1 transgenic mice.  
Contrast to the initial belief that overexpression of wild type SOD1 cannot 
lead to ALS, recent study of mouse model with human wild type SOD1 expressed 
at the similar level of mutant SOD1 expression level in G93A mouse revealed that 
excess human wild type SOD1 can cause progressive motor neuron degeneration 
(58).  
1.4.2 TARDBP mouse models of ALS 
Since the link between TARDBP and ALS was built in 2006 (30), a lot of 
effort has been put to generate TARDBP mouse models of ALS. TDP43 positive 
cytoplasmic inclusions were found in almost all ALS patient samples, accompanied 
by the nuclear depletion of TDP43 (30). TDP43 is a 43kD protein, encoded by the 
gene TARDBP. TDP43 contains two RNA recognition motifs, one nuclear-
localization signal, and a C-terminal glycine rich domain, where almost all of the 
pathogenic mutations for ALS were identified (31). TDP43 has been shown to be 
involved in regulation of gene expression, alternative splicing, and neuronal 
development (31, 35, 59). But it is unknown how the mutations in TDP43 could 
lead to the development of ALS. Two mechanisms, gain-of-toxicity and loss-of-
function, have been proposed and debated for a long time in the field. More than 
twenty TDP43 mouse models have been generated to study the biological and 
pathological functions of the protein.  
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1.4.2.1 TARDBP knock out mouse model 
Because the nuclear depletion of TDP43 was observed in ALS patients (30), 
TARDBP knock-out mouse model was made to determine whether loss of normal 
TDP43 function could cause ALS, as well as to investigate the biological function 
of TDP43. Several groups reported independently that complete loss of TDP43 
leads to embryonic lethality, implying that TARDBP is an essential gene for 
development in mice (60-63). Then, researchers tried heterozygous knock out 
strategy. Although age-dependent deficits in grip strength and cage-hanging tests 
were reported, the mRNA and protein levels of TARDBP were not changed in this 
mouse model in which one allele of TARDBP was disrupted (61). This result was 
in accordance with the findings that TDP43 is auto-regulating its own expression 
by binding to its 3’UTR (35, 64).  
Another way to tackle the embryonic lethality issue is to use conditional 
knock out strategy. Theoretically, we can induce the knockout of TARDBP in a 
spatial or temporal specific manner. One group from John’s Hopkins Medical 
School made a conditional TARDBP homozygous knockout mice, in which 
TARDBP could be knocked out in adult. Rapid loss of body fat weight and quick 
death were observed in this mouse model (60). But the fat loss was so quick that 
there was not enough time to develop any neuron degeneration phenotype. This 
conditional TARDBP knock out mouse model failed to recapitulate any ALS 
associated symptoms.  
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Wu et.al generated a spinal cord motor neuron specific TDP43 mouse 
model by crossing the mice with Tardbp conditional allele (Tardbplx) with mice with 
cre-recombinase transgene under the control of HB-9 promoter (65). HB9 is a 
transcription factor that is specifically expressed in motor neurons of developing 
spinal cord. Therefore HB9: cre mice can induce cre-recombinase expression 
specifically in spinal cord motor neurons. In this HB9+ cell TDP43 knock-out mouse 
model, ALS-related phenotypes were observed, including motor dysfunction, 
muscle weakness. Choline acetyltransferase (ChAT) levels were reduced in this 
mouse model, and this result was in accordance with the progressive loss of ChAT-
positive spinal cord motor neurons, accompanied by gliosis (65). It is worth noticing 
that TDP43 protein level in this spinal cord motor neuron specific knock-out mice 
was not changed (65). It is probably because HB9-positive motor neurons only 
account for a small proportion of the whole population in spinal cord. 
1.4.2.2 TARDBP transgenic mouse models 
Several promoters have been utilized to drive exogenous TARDBP, human 
or mouse, wild type or mutant, in specific regions of mice, usually in neuronal 
system. Among them, the mouse Prion promoter is the most widely used one. 
Prion promoter can drive transgene expression in the central nervous system (66). 
Other neuronal promoters were also used to generate TDP43 transgenic mouse 
models. Thy1.2 promoter can drive transgene expression in neuronal cells one 
week postnatal (67). This special switch on time point bypasses the serious 
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problems caused by TDP43 overexpression during embryonic development. The 
third neuronal specific promoter commonly used is CaMKII promoter. CaMKII can 
restrict the transgene expression within the forebrain (68). As such transgenic 
mouse based on CaMKII promoter facilitate the investigation of the function of 
TDP43 in upper motor neurons.  
Human wild type TDP43 and mouse wild type TDP43 overexpression 
mouse models were developed using all of the three neuronal promoters by 
different groups. Although the result supports each other in some aspects, they 
are not completely consistent. N.R Stallings et.al reported that overexpression of 
human wild type TDP43 under mPrp promoter at the level of 3-4 folds more than 
the endogenous TDP43 cannot induce any ALS phenotype although in the spinal 
cord, mild gliosis and ubiquitin aggregation were observed (69). However another 
group from Mayo clinic reported that under the same promoter, 1.9-2.5 folds of 
human wild type TDP43 overexpression over the endogenous TDP43 level could 
result in severe neuron degeneration and shorter life span (70).  
If human TDP43 overexpression was introduced with Thy1.2 promoter, the 
transgene expression is turned on from one week of age (67). One group 
discovered an interesting sexual variation. In female mice, human wild type TDP43 
at 1.9 fold of endogenous TDP43 expression level was induced, and no significant 
symptom other than mild tremor was observed. However in male mice, higher level 
of human wild type TDP43, at 3.6 fold of endogenous level, was induced, and 
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abnormal hind limb reflexes, tremor, as well as altered gait was seen as early 2 
weeks old. In both genders, motor neurons were positive of cytoplasmic 
aggregations with mitochondrial markers (67).  
In wild type TDP43 transgenic mouse models under the control of CaMKII 
promoter, 2 fold of mouse wild type TDP43 overexpression led to cognitive defects 
at 8 weeks old. Additionally multiple motor deficits were reported, including 
abnormal hindlimb reflexes, impaired rotarod performance and reduced grip 
strength, accompanied with significant 26% loss of cortical neurons (68).  
ALS disease related mutations in TDP43, such as M337V and A315T, were 
introduced into mouse model using mPrp promoter (71, 72). Similar phenotypes 
as those observed in wild type TDP43 overexpression mouse models were 
reported. Those mice developed abnormal gait and loss of upper and lower motor 
neurons, as well as axonal degeneration were also observed.  
In all of the TDP43 overexpression mouse models mentioned above, the 
toxicity was dose-dependent. H.Wils et.al did an in-depth analysis of this dose 
effect with three lines of mice expressing human wild type TDP43 at various levels 
(73). In the lowest expression line, human wild type TDP43 was expressed at level 
of 1-fold endogenous TDP43. No motor dysfunctions were observed until 15 
months age, and the lifespan was not affected. In the intermediate expression line, 
human wild type TDP43 was 3.8 fold higher than the endogenous TDP43, and 
these mice showed motor dysfunction by 4 months old. Motor dysfunction was 
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observed even earlier, at 18 days old, in the high-expressing line, in which human 
wild type TDP43 was expressed 5 fold higher than the endogenous TDP43 (73). 
This dose-dependent toxicity could be explained by autoregulation of TDP43 of its 
own mRNA expression level, as many other RNA regulatory proteins. It’s been 
found that TDP43 auto-regulate its mRNA transcript level by binding to the 3’UTR 
of its mRNA (64). Therefore overexpression of exogenous TDP43, no matter wild 
type or mutants, as long as it remains the function of binding to the 3’UTR of its 
mRNA, the endogenous TDP43 expression level is down regulated, thus causing 
the down regulation of normal TDP43 function.   
1.5 Molecular mechanism of TDP43-mediated neurodegeneration 
1.5.1 TDP43 is central to the pathogenesis of ALS 
Following the discovery that TARDBP was associated with ALS, the 
advances in human genetics have greatly enlarged the family of ALS-associated 
genes: FUS, UBLN2, OPTN, ATXN2, C9ORF72 et.al are also included (12-18). 
But the striking fact that most ALS patient, except those with SOD1 or FUS 
mutations, exhibits TDP43 pathology, e.g., cytoplasmic TDP43 inclusion is 
observed, together with the nuclear clearance of TDP43 (30), puts TDP43 central 
of ALS pathogenesis. What’s more, although TDP43 pathology was not seen in 
ALS patients with FUS mutations (74), studies in Drosophila indicated that TDP43 
and FUS are in the same genetic pathways. FUS interacts with TDP43, suggesting 
that TDP43 and FUS mechanistically act together to cause ALS (75). Moreover, 
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there’s evidence showing that ALS-associated mutations in TDP43, such as 
Q331K and M337V, could increase the interaction of TDP43 and FUS (76, 77). It 
is possible that the mutations in TDP43 significantly increase the half-life of the 
protein.  
The link between the abnormal expansions of the intronic hexanucleotide in 
C9ORF72 with ALS, which was discovered in 2011 (75), draws great attention to 
this functionally unknown gene, because mutations in C9ORF72 account for 40% 
of FALS cases and 7% SALS cases (75). Even so, TDP43 pathology still exist in 
C9ORF72 mutation carrying ALS patients (31). Therefore, TDP43 remains the 
crucial role in the onset and progress of ALS. Studies regarding the normal 
functions of TDP43, the post-translational modifications in TDP43, the cytoplasmic 
inclusion of TDP43 formed in ALS patients, and the nuclear clearance of TDP43 
still require more efforts in the field of motor neuron degeneration.  
1.5.2 The normal functions of TDP43 
TAR DNA-binding protein43 (TDP43), encoded by the gene TARDBP, is a 
protein consists of 414 amino acids. There are two RNA recognition motifs (RRM), 
one nuclear localization signal (NLS), and a glycine-rich carboxyl terminal domain 
in TDP43 (Fig 1.1).  
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Fig 1.1 Cartoon illustration of TDP43 protein  
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The C-terminal glycine-rich domain is required for interaction of TDP43 with 
heterogeneous nuclear ribonucleoprotein (hnRNP) family of proteins (78, 79), and 
almost all of the ALS-associated mutations were found in this glycine-rich domain. 
The two RRMs are important for TDP43 to bind RNA/DNA, and the first RRM is 
believed to mediate TDP43 binding to single-stranded RNA (80-83). High through-
put sequencing results from two independent groups indicated that in mouse brain, 
TDP43 binds to more than 6,000 mRNA species, mostly in introns, 3’UTRs, and 
non-coding RNAs. Large amount of those TDP43 binding mRNAs are long 
transcripts, and those transcripts involved in neuronal development (35, 59). There 
is a consensus that TDP43 binds to GU-rich sequences in mRNA. However GU 
sequence is neither necessary nor sufficient for TDP43 binding (25, 26, 35, 59, 83).  
It’s worth noticing that TDP43 also binds to the 3’UTR of its own mRNA, auto 
regulating its own MRNA transcript level (64). How does TARDBP regulates its 
own mRNA transcript level with binding to the mRNA 3’UTR is unclear, although 
there are several hypothesis proposed by different groups. One group proposed 
that by binding to the 3’UTR, TDP43 can enhance the splicing of an intron, 
triggering nonsense-mediated decay of its mRNA. Another group got an opposite 
conclusion, citing that upon TDP43 binding to its mRNA, the instability of the 
mRNA increases, leading to the reduction of nuclear TDP43 level and the increase 
of new TDP43 protein synthesis.  
Consistent with the interaction of TDP43 with mRNAs and hnRNPs, the 
major function of TDP43 reported so far is regulating splicing of various genes (Fig 
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1.2), such as survival of motor neurons (SMN), histone deacetylase 6 (HDAC6), 
FUS, and the NF-L neurofilament subunit (27). Data from cell culture and the adult 
mouse nervous system revealed that depleting TDP43 could lead to the changes 
of abundance of more than 600 mRNA and splicing patterns of nearly 1000 mRNA  
(59).  But consensus haven’t emerged on which direction TDP43 will alter the 
slicing patterns. For some genes, depleting TDP43 enhanced the exclusion of 
some exons, but for others, depleting TDP43 enhanced the inclusion of some 
exons (59).  
Furthermore, TDP43 was also found to be involved in miRNA biogenesis 
(Fig 1.2), supported by the finding that TDP43 normally localizes to the 
perichromatin fibers, where miRNA is thought to be generated (77, 84-86). Another 
piece of evidence supported the conclusion that TDP43 regulates miRNA 
biogenesis. TDP43 was confirmed to interact with primary miRNA processing 
Drosha complex. Finally, knock down of TDP43 changed the expression level of 
various miRNAs (77, 84-86). 
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Fig 1.2 TDP43 normal functions  
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1.5.3 ALS related TDP43 post-translational modifications 
A hallmark of neurodegenerative disease is the occurrence of cytoplasmic 
inclusions containing different disease causative proteins, such as huntingtin in 
Huntington’s disease, and α-synuclein in Parkinson’s disease, and TDP43 in ALS. 
Under normal conditions, these inclusions are rarely seen. So the inclusions are 
thought to be pathogenic indicators of various neurodegenerative diseases. Post-
translational modifications, including ubiquitylation and phosphorylation, are 
commonly seen for those disease-associated proteins in cytoplasmic inclusion. 
There are two types of cytoplasmic inclusions in ALS patients. Besides the usual 
inclusions, there is some less dense granules, termed ‘pre-inclusion’, occurred in 
ALS. TDP43 in those pre-inclusions are not ubiquitylated, but phosphorylated (87, 
88). TDP43 in the usual inclusions are both ubiquitylated and phosphorylated, 
suggesting that phosphorylation happens at a relatively early stage, while 
ubiquitylation is a later stage modification. It’s not totally clear why TDP43 is 
ubiquitylated under pathogenic conditions. It’s believed that TDP43 is cleared out 
of the cell through ubiquitin-proteasome system (UPS), and disruption of UPS 
leads to elevated ubiquitylation. Although phosphorylation is readily seen in 
aggregated TDP43 in ALS patients and animal models, there is no consensus now 
whether phosphorylation is the cause of aggregation or the consequence of 
aggregation. Mutated TDP43 proteins are not more prone to phosphorylation and 
phosphorylation does not seem to be required for TDP43 aggregation, cleavage, 
and toxicity in cell cultures (89, 90).  
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The 25-kD and 35-kD truncated TDP43 fragments were found in brains of 
ALS patients as well as in various animal models (30, 91). These carboxyl terminal 
fragments (CTF) are presumably generated by proteolytic cleavage of full-length 
TDP43.  Therefore, CTFs lack NLS, rendering them to remain in the cytoplasm. 
The role of CTFs on ALS onset and progress is unclear, but it is hypothesized that 
these CTFs retain the function to interact with other RNA-binding proteins, especial 
hnRNPs. They compete with functional full-length TDP43 to form complexes with 
other proteins, leaving the complexes non-functional. Moreover, CTFs could 
attract normal full-length TDP43 into cytoplasmic inclusions, further reducing 
TDP43 functions within the cells.  
1.5.4 Nuclear clearance of TDP43 and ALS development 
TDP43 is primarily a nuclear localizing protein (30). It contains both NLS 
and NES, so TDP43 is able to shuttle between nucleus and cytoplasm under 
normal conditions. Cytoplasmic localization of TDP43 is very limited in normal 
people. However, in ALS patients, cytoplasmic TDP43 aggregates are readily seen, 
accompanied with the clearance from nucleus (30). It is not surprising that ALS-
associated A90V TDP43 mutation increases TDP43 mislocalization to the 
cytoplasm, because the mutation is between the two NLS, thus probably alter the 
characteristics of the two NLS (92). Besides the genetic changes, environmental 
factors, such as oxidative stress, can also cause TDP43 to translocate to the 
cytoplasm. For example, oxidative stress introduced by arsenite treatment will 
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increase the redistribution of TDP43 to the cytoplasm and recruitment to stress 
granules (10).  
Researchers have generated cell culture systems as well as transgenic 
mouse model to study the significance of the mislocalization of TDP43. Mutations 
in NLS render TDP43 to be cytoplasmic in one transgenic mouse model (92). 
Neurodegeneration was observed in this mouse model. However, as discussed 
previously, overexpression of wild type TDP43 also led to neurodegeneration, 
although might be milder (70). So it seems that cytoplasmic localization of TDP43 
is not required to cause ALS. How the mislocalization affects TDP43 function and 
how it is associated with ALS disease onset and progress need more research.  
A direct and ultimate answer to the question that whether nuclear clearance 
itself would result in neurodegeneration can be obtained from animal models with 
TARDBP knock out or knock down. However, as mentioned before, TARDBP was 
proved to be a developmental essential gene because knocking out TARDBP led 
to embryonic lethality (61-63). Even if TARDBP was knock out postnatal, the mice 
still displayed abnormalities, such as quick fat loss (60). Therefore a more 
sophisticated mouse model with reduced TDP43 expression level in the nucleus is 
eagerly needed, because although the cytoplasmic TDP43 could possibly still 
retain its RNA and other protein binding functions, it needs to be at the right place 
to exert its full function.  
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Chapter II 
Making a conditional TARDBP knock down 
mouse model 
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2.1 Abstract 
TAR DNA-binding protein 43 (TDP43) proteinopathy and nuclear clearance 
are observed in about 95 percent of amyotrophic lateral sclerosis (ALS) patients, 
except those with SOD1 or FUS mutations. The cytoplasmic TDP43 forms 
aggregates, and undergoes post-translational modifications, such as ubiquitylation 
and phosphorylation. Results from cell culture system and animal models showed 
that overexpression of exogenous TDP43, no matter wild type or mutants, led to 
TDP43 aggregates formation and neuron loss. These observations pointed to the 
gain-of-toxicity mechanism of TDP43 in causing neurodegeneration. However 
because the nuclear clearance of TDP43 occurred simultaneously with 
cytoplasmic aggregates formation, the possibility that loss of normal TDP43 
function also contributes to neurodegeneration cannot be excluded. Indeed, the 
cytoplasmic TDP43 in aggregates could attract and sequester wild type TDP43, 
therefore causes TDP43 dysfunction. Furthermore, since TDP43 is such a crucial 
player in numerous cellular processes, the loss of TDP43 function results in neuron 
death. Embryonic lethality of TARDBP knockout mice indicated the essential role 
of TDP43 during embryonic development. A more sophisticated mouse model that 
could avoid embryonic lethality is eagerly needed. Here, we used tetracycline-
controlled transcription activation system to make a conditional TARDBP knock 
down mouse model. By crossing with different tetracycline transactivator lines, we 
can control TARDBP knock down in a space or temporal specific manner, 
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facilitating our understanding of TDP43 normal function and the effect of TDP43 
dysfunction in ALS development.  
2.2 Introduction 
TAR DNA-binding protein (TARDBP) encodes a protein consisting of 414 
amino acids. The name of this gene came from the discovery that it could interact 
with the HIV-1 TAR DNA sequence motif (93). As its name suggests, the product 
of TARDBP, protein TDP43 can bind to both DNA and RNA, due to the two RNA 
recognition motifs (RRM) found in its N-terminus. TDP43 contains two nuclear 
localization signals (NLS) between the N-terminus and RRM1, and one nuclear 
export signal (NES) within RRM2. Thus, TDP43 is shuttling between nucleus and 
the cytoplasm. Under normal conditions, TDP43 is dominantly nuclear. A striking 
fact is that TDP43 proteinopathy, e.g. the cytoplasmic translocation and inclusion 
of TDP43, is observed in around 95 percent of ALS (88), although about 50 ALS-
associated mutations in TARDBP only account for 5 percent of FALS (30, 91), 
which as a whole is only 10 percent of all ALS cases. The common TDP43 
proteinopathy found in most ALS cases put TDP43 in the central of ALS disease 
research. Numerous animal models as well as cell culture systems have been 
generated to study the normal functions and effects of TDP43 in 
neurodegeneration and ALS development (60, 62, 63, 65, 67-70, 72, 77).  
The coincidence of cytoplasmic aggregate formation and nuclear clearance 
of TDP43 in ALS patients (30, 91) guides the study of TDP43 into two directions. 
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On one hand, wild type and mutant TDP43 were introduced to mouse models. 
Although the symptoms of these mouse models were not completely the same, the 
consensus emerged that overexpression of TDP43 resulted in the cytoplasmic 
translocation of TDP43 and subsequent aggregation and post-transcriptional 
modification, leading to neurodegeneration and neuron loss (68-71, 73). These 
evidence pointed to gain-of-toxicity mechanism for TDP43 to cause 
neurodegeneration.  
However, the fact that endogenous TDP43 were attracted and sequestered 
to the cytoplasmic inclusions and the expression of endogenous TDP43 as well as 
its nuclear localization was reduced makes the situation complicated to analyze. 
We cannot exclude the possibility that the normal function of TDP43 was 
compromised, and TDP43 dysfunction also contributed to neurodegeneration in 
those mouse models and furthermore in ALS patients. The ultimate question is 
whether TDP43 loss-of-function also contributes to ALS development, and 
whether loss-of-TDP43 function itself is sufficient to induce neurodegeneration.  
To answer this question, the most direct and ultimate method is to make 
TDP43 knockout mice, in which endogenous TDP43 is completely depleted. The 
biggest hurdle to this strategy is that TARDBP knockout mouse is embryonic lethal 
(61-63). It is not surprising because TDP43 is an important regulator for mRNA 
splicing, transport, stability, and miRNA biogenesis (77, 84-86). It has been 
reported that TDP43 binds to more than 6,000 mRNA in mouse brain, among 
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which a lot are related to neuronal development (76). One of the strategy to avoid 
the embryonic lethality is to make inducible TARDBP knockout mouse model. 
Another alternative is to make conditional TARDBP knockdown mouse model 
based on tetracycline-controlled transactivation system, e.g. tet-on/tet-off system. 
One of the advantages of tet-on/tet-off based TARDBP knockdown system over 
conditional TARDBP knockout mouse model is that in tetracycline controlled 
knockdown system, the knockdown can be technically reversed. What’s more, by 
using various tetracycline transactivator under different promoters, we can restrict 
the knockdown of TARDBP in specific cell types, such as motor neurons, 
astrocytes, so that we can better study the requirement of neurodegeneration in 
terms of TDP43 expression. The success of tetracycline based TARDBP 
conditional knockdown mouse model system is two folds. One is to make mouse 
lines harboring miRNA targeting TARDBP, and to put this miRNA sequence under 
the control of tetracycline response element (TRE). The other is to find proper 
tetracycline transactivator lines that can control miRNA expression in response to 
tetracycline.  
2.3 Result 
2.3.1 TRE-mCherry-amiTDP43 responds to tetracycline and induces 
transgenic mCherry expression as well as TARDBP knockdown in vitro 
To generate tet-on/tet-off system based conditional TARDBP knockdown 
model, Chunxing, a postdoctoral fellow in Xu lab, designed and tested a pool of 
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shRNA targeting TDP43, and chose one sequence that was best at knocking down 
TARDBP in cell culture (94). Then, I incorporated the stem sequence into the pre-
miR-30a structure to make miTDP43 (unpublished data). We put mCherry, a red 
fluorescent protein, behind a Tet-responsive Ptight promoter used as an indicator of 
transgene expression and a tracer for future screening. It was previously reported 
that incorporating miRNA into an artificial intron and then putting this miRNA-
containing intron into the 3’UTR of a fluorescent protein gene, did not affect miRNA 
expression, and enhanced the expression of the fluorescent protein (95). We 
adopted this strategy and put miTDP43 into an artificial intron that has been 
generated and tested in the lab. Then this miTDP43-containing intron was further 
incorporated into the 3’UTR of mCherry, so that a construct with mCherry and 
miTDP43 expressing simultaneously and under the control of Tet-responsive Ptight 
promoter was generated (Fig 2.1 A), and was named TRE-mCherry-amiTDP43. 
Next, we tested whether the construct TRE-mCherry-amiTDP43 could be 
induced in cell culture and knock down endogenous TARDBP.  Tet-on system was 
adopted for this purpose. We co-transfected NSC34 cells with TRE-mCherry-
amiTDP43 and CAG-rtTA. The reversed tetracycline transactivator produced by 
CAG-rtTA turned on the expression of mCherry and amiTDP43 with addition of 
tetracycline or doxycycline, a derivative of tetracycline. mCherry fluorescence was 
checked 72 hours after transgene induction. Compared with control without 
addition of doxycycline, robust induction of mCherry fluorescent protein was 
observed under the fluorescent microscope (Fig. 2.1 B), indicating the success to 
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control transgene expression in a tetracycline responsive manner. Then, protein 
was harvested from all three differently treated cell cultures: mock without 
transfection of any plasmid, control with both CAG-rtTA and TRE-mCherry-
amiTDP43, but no doxycycline, and sample with both plasmids and doxycycline. 
As shown in western blot (Fig 2.1 C), after 72 hours’ induction, mCherry was readily 
detected, and TDP43 was knocked down accordingly.  Very little leakage was seen 
in control without adding doxycycline.  
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Fig 2.1 Generating TRE-mCherry-amiTDP43 and testing the transgene 
induction and TARDBP knock down in vitro. (A) Cartoon illustration of construct 
making strategy and tet-on system. MiTDP43 was put into an artificial intron, and 
this miTDP43-containing intron was incorporated into the 3’UTR of mCherry. Both 
mCherry and miTDP43 was under control of Tet-responsive Ptight promoter. Cells 
co-transfected with TRE-mCherry-amiTDP43 and CAG-rtTA did not turn on the 
expression either gene until the addition doxycycline, which facilities the binding to 
rtTA protein to TRE, and induce the gene expression. In this system, mCherry 
serves as a reporter of miTDP43 expression and makes the subsequent screening 
process easy and efficient. MiTDP43 knocks down the endogenous TDP43. (B) 
Response of the tet-on system described in A was tested in NSC34 cells. NSC34 
was co-transfected with TRE-mCherry-amiTDP43 and CAG-rtTA, and was 
incubated with or without doxycycline for 72 hours. With doxycycline, the 
expression of mCherry was readily detectable under fluorescent microscope. Little 
red signal in doxycycline- control indicated very limited leakage of the system. (C) 
mCherry expression and TARDBP knock down was confirmed with western blot 
assay. Proteins lysates from mock control (no plasmid, with doxycycline), negative 
control (both plasmids, without doxycycline), and sample (both plasmids, with 
doxycycline) were analyzed with western blot assay. With doxycycline, mCherry 
was successfully induced, and TARDBP knock down compared with the TDP43 
expression levels in mock and negative control suggested the simultaneous 
expression of amiTDP43 with mCherry and its function to knock down TARDBP. 
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Fig 2.1 Generating TRE-mCherry-amiTDP43 and testing the transgene 
induction and TARDBP knock down in vitro. 
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2.3.2 TRE-mCherry-amiTDP43 transgenic mouse was successfully 
generated and 2 independent lines were screened out  
TRE-mCherry-amiTDP43 plasmid was linearized and the larger fragment 
containing Tet-responsive element as well mCherry and amiTDP43 expression 
components was micro-injected into the embryo of a superovulated female mouse 
as previously described. The pseudopregnant mouse gave birth to 108 founder 
mice. All the founder mice were genotyped for mCherry transgene using common 
tail DNA extraction and genotyping protocol. The 27 mCherry+ mice were 
considered F0 and crossed with mPrp-tTA mouse. All F1 mice got were genotyped 
again for confirmation of existence of mCherry transgene. Fluorescence check of 
mCherry and western blot analysis of mCherry and TDP43 in forebrain were 
carried out to further confirm the transgene expression. Seven F1 lines with strong 
mCherry expression were kept for F2 screening. The same measurements were 
applied to F2 mice, and 3 lines were screened out with 2 of them kept for further 
analysis based on three criteria: 1) robust mCherry expression. In both remaining 
lines, mCherry was so strongly expressed that sometimes the red fluorescence 
was seen with naked eyes in tail, ear and dissected forebrain; 2) the expression of 
mCherry was strong and evenly distributed in forebrain; 3) incidence rate of 
hyperactivity was high. Very often, we observed hyperactivity in some TRE-
mCherry-amiTDP43/mPrp-rtTA double transgenic mice (dtg mice thereafter), and 
this hyperactivity was associated with transgene expression. The screening 
process was summarized in Figure 2.2. Unfortunately, the expression of mCherry 
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and amiTDP43 was not seen in spinal cord as anticipated, thus the lower motor 
neuron associated paralysis was not observed as a result (described in detail in 
later parts). 
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Fig 2.2 Making TRE-mCherry-amiTDP43 transgenic mice and screening 
strategy. The linearized fragment from TRE-mCherry-amiTDP43 containing Tet-
responsive Ptight promoter and mCherry as well amiTDP43 expression elements 
was micro-injected into a superovulated female mouse. And 108 founder lines born 
by the pseudopregnant mouse was genotyped for mCherry transgene. Then 27 
lines with positive mCherry DNA was used as F0 to cross with mPrp-tTA. All the 
F1 mice were genotyped for mCherry and checked for mCherry fluorescence with 
fluorescent microscope. Western blot analysis was used to confirm the expression 
of mCherry. Seven promising F1 mice were crossed with mPrp-tTA mouse again 
to further screen for the stably expressed lines. The same measurements were 
used for F2 screening. Two out of the three screened out lines were chosen for 
further analysis based on three criteria: 1) robust mCherry expression in forebrain; 
2) even distribution of mCherry in forebrain; 3) high incidence of hyperactivity.  
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Fig 2.2 Making TRE-mCherry-amiTDP43 transgenic mice and screening 
strategy. 
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2.3.3 Transgenic mCherry was expressed in mouse forebrain cortex and 
cerebellum, but not in spinal cord and other tissues. 
mPrp-tTA was expected to restrict the expression of transgene under the 
control of Tet-responsive promoter within central nervous system, including 
forebrain and spinal cord (66). Because ALS affect both upper motor neurons and 
lower motor neurons, we chose mPrp-tTA mouse to cross with TRE-mCherry-
amiTDP43 transgenic mouse, in order to drive mCherry expression and TARDBP 
knock down in both forebrain and spinal cord. Western blot analysis was first used 
to determine the tissue distribution of mCherry expression (Fig 2.3 A). As expected, 
mCherry was not detected in tissues other than central nervous system. However, 
mCherry was not seen in spinal cord either. The reason why this tTA line did not 
work as expected was not clear. Sometimes, the mCherry expression was 
detectable in skin so that mouse tail and ear displayed red color. DAB staining with 
antibody recognizing mCherry revealed forebrain mCherry expression pattern in 
detail (Fig 2.3 B). Positive mCherry staining was observed in olfactory bulb, 
forebrain cortex, and cerebellum areas. Enlarged image showed that mCherry was 
not ubiquitously expressed in forebrain. The positive signal was mostly seen in 
cells with neuron morphology (Fig 2.3 B). And the expression strength was not 
universal in different regions of the forebrain. In motor cortex (marked as region 1 
in Fig 2.3 B), mCherry signal was much fainter than that seen in somatosensory 
cortex.   
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Fig 2.3 mCherry was expressed in forebrain cortex and cerebellum, but not 
in spinal cord and other tissues. (A) The mCherry transgene distribution was 
determined with western blot analysis. Protein was extracted from quick-frozen 
tissues and homogenized in lysis buffer. Equal amount of total protein was loaded 
for detection of mCherry expression. Tubulin was used as a loading control. 
mCherry expression was very strong in mouse forebrain and cerebellum, but not 
detectable in other tissues, including spinal cord. (B) DAB staining using anti-RFP 
antibody to reveal mCherry expression pattern within forebrain. Positive signal was 
detected in cells with neuronal morphology, and mCherry expression strength was 
different in various regions. As marked with numbers, the enlarged imaged showed 
that mCherry was more moderately induced in primary motor cortex region than in 
primary somatosensory cortex region.   
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Fig 2.3 mCherry was expressed in forebrain cortex and cerebellum, but not 
in spinal cord and other tissues. 
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2.3.4 mCherry expression was restricted to neurons in mouse forebrain 
To make sure that the expression of mCherry and amiTDP43 was restricted 
to neurons, and other cell types, especially astrocytes and microglia do not express 
the transgene in double transgenic mice, we used antibody against Glial fibrillary 
acidic protein (GFAP) to stain astrocytes (Fig 2.4 B’), antibody against ionized 
calcium-binding adapter molecule 1 (IBA1) to stain microglia (Fig 2.4 C’), and 
antibody against NeuN to stain neurons (Fig 2.4 A’) (96). The overlap of NeuN 
signal and mCherry signal (Fig 2.4 A’’) clearly demonstrated the expression of 
mCherry in neurons. Nevertheless, no co-localization was observed for mCherry 
signal and GFAP or IBA1 signal, suggesting that mCherry and amiTPD43 did not 
express in glia cells in double transgenic mice. 
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Fig 2.4 mCherry was expressed in neurons, but not in glia cells. Antibodies 
against NeuN (A’), Glial fibrillary acidic protein (GFAP) (B’), and ionized calcium-
binding adapter molecule 1 (IBA1) (C’) were used to stain neurons, astrocytes, and 
microglia cells respectively. Co-localization of mCherry with NeuN staining was 
observed (A’’), while co-localization of mCherry with GFAP (B’’) and IBA1 (C’’) was 
not seen.  
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Fig 2.4 mCherry was expressed in neurons, but not in glia cells. 
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2.3.5 amiTDP43 expression was coupled with mCherry expression, and in 
mCherry positive cells, TARDBP was knocked down.   
In our TRE-mCherry-amiTDP43 construct design, mCherry was supposed 
to serve as a reliable indicator of amiTDP43 expression. This assumption must be 
confirmed with assays to measure amiTDP43 expression level. We measured 
amiTDP43 expression level in double transgenic mice (dtg) with real-time PCR. As 
a control, amiTDP43 expression level was also checked in single transgenic mice 
(stg). The result revealed a 70 fold increase of amiTDP43 expression in dtg mice 
compared with that in stg mice (Fig 2.5 A). Accordingly, although only around 30% 
of neurons expressed mCherry, in those mCherry positive cells, TDP43 staining 
was significantly reduced comparing with that in mCherry negative cells (Fig 2.5 B, 
arrowheads), indicating knock down of TARDBP by amiTDP43 induction.  
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Fig 2.5 amiTDP43 was highly expressed in double transgenic mice, and 
TARDBP was knock down in mCherry positive cells. Total miRNA was isolated 
from forebrains of double transgenic and single transgenic mice, and real-time 
PCR was applied to measure the expression level of amiTDP43 in stg mice and 
dtg mice. The result showed a 70 fold increase of amiTDP43 expression in dtg 
mice compared with amiTDP43 expression in stg mice (A). N=5 for single-
transgenic. N=11 for double-transgenic. Immuno-staining of TDP43 was 
performed to confirm that coupled with mCherry expression, amiTDP43 
expression was induced, thus endogenous TDP43 was knocked down. The 
arrowheads (B) pointed out that in mCherry positive cells, the staining of TDP43 
was significantly reduced or hardly seen, suggesting that TARDBP was knock 
down by the induced amiTDP43. Error bars indicate SEM.  
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Fig 2.5 amiTDP43 was highly expressed in double transgenic mice, and 
TARDBP was knock down in mCherry positive cells. 
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2.3.6 Hyperactivity was observed in some double transgenic mice, and the 
hyperactivity was more related to mCherry expression strength than 
TARDBP knock down level.  
Hyperactivity was observed in double transgenic mice from all of the three 
screened out lines. In those two lines kept for further analysis, the rate of 
hyperactivity was 16.67% (12 hyperactive dtg mice out of 72 dtg mice in total) and 
36.36% (16 hyperactive dtg mice out of 44 dtg mice in total). The hyperactivity 
seemed to be transgene associated, because almost all of the hyperactive mice 
were TRE-mCherry-amiTDP43 and mPrp-tTA double transgenic. Among more 
than 3,000 mice that had been checked and/or analyzed during the screening and 
analysis process, only 1 mPrp-tTA mouse and 6 TRE-mCherry-amiTDP43 single 
transgenic mice showed similar hyperactivity for some time. Others were all normal. 
We randomly picked 5 mice with matched age for each of the four groups to 
perform home-cage scan analysis: non-transgenic mice (non-tg), single transgenic 
mice (stg), double transgenic mice without hyperactivity (dtg), and double 
transgenic mice with hyperactivity (dtg*). The home-cage scan analysis (Fig. 2.6 
A) compared the mice from the four groups in travel distance, exploratory time, 
vertical movement, and feeding time. The result confirmed that dtg* mice travelled 
significantly more than the other three groups, while they spent less time in other 
activities, including exploration, vertical movement and feeding. Thus, the body 
weight of those dtg* mice were lighter than their littermates control. But progressive 
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or sudden body weight loss often seen in neurogenerative mouse models was not 
observed.  
We speculated that the hyperactivity was caused by more severe TARDBP 
knock down in hyperactive dtg* mice than that in non-hyperactive dtg mice. To test 
this hypothesis, brain sections from 5 dtg* mice and 5 dtg mice were stained with 
TDP43 antibody, and the fluorescent strength of TDP43 signal and mCherry signal 
was quantified in each section. In Fig 2.6 B, each dot represented a single 
mCherry+ cell. X axis was mCherry fluorescence strength normalized to the 
background level. Y axis was TDP43 fluorescence strength normalized to that of 
mCherry- cells. The plot revealed that dtg* mice and dtg mice were not different in 
terms of TDP43 knock down level. Expression of TDP43 dropped down to around 
50% of that in mCherry- cells in both groups. However, mCherry expression level 
was much higher in dtg* mice. This conclusion was further strengthened in Fig 2.6 
C. Brains from 5 dtg* mice and 5 dtg mice were dissected out and images were 
taken of these mouse brains under bright field and fluorescent lens. mCherry 
expression level was higher in dtg* mice, especially in forebrain cortex, in which 
mCherry fluorescence signal was hardly detectable with fluorescence camera, 
while in dtg* mice, mCherry signal was very strong and evenly distributed in 
forebrain cortex.  
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Fig 2.6 Hyperactivity was observed in some TRE-mCherry-amiTDP43/mPrp-
tTA double transgenic mice. Home-cage scan to verify and quantify the 
hyperactivity was performed (A). 5 mice from each of the following four groups 
were analyzed with home-cage scan: non-transgenic mice (non-tg), single 
transgenic mice (stg), double transgenic mice without hyperactivity (dtg), and 
double transgenic mice with hyperactivity (dtg*). Travel distances, vertical 
movement, feeding time, and exploration time were recorded and analyzed. 
TDP43 immunostaining was performed in forebrain sections from 5 dtg and 5 dtg* 
mice. mCherry fluorescence strength and TDP43 fluorescence strength were 
normalized and plotted for each single cell (B). The average of TDP43 expression 
levels were shown in bar graphs (B). In dtg* mice, mCherry fluorescence strength 
was significantly higher in forebrain and cerebellum than that in dtg mice (C). N=5 
for each group in (A). N=49 for non-hyperactive double tg, N=45 for hyperactive 
double tg in (B). Error bars indicate SD. **, p<0.01. N.S=not significant.  
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Fig 2.6 Hyperactivity was observed in some TRE-mCherry-amiTDP43/mPrp-
tTA double transgenic mice. 
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2.3.7 Astrocyte activation and neuron loss were not observed in TRE-
mCherry-amiTDP43/mPrp-tTA double transgenic mice.  
Hyperactivity is usually linked with neurodegeneration and neuron loss in 
forebrain (97-101). To examine whether the hyperactivity we observed in some 
double transgenic mice causes neurodegeneration, sections from non-transgenic 
(non-tg) control, double transgenic without hyperactivity (dtg) mice, and double 
transgenic with hyperactivity (dtg*) were stained with Nissl to visualize neurons. 
Neuron numbers were counted in all three groups, and neuron number was not 
different among the three groups (Fig 2.7 A), suggesting that there was not obvious 
neurodegeneration undergoing in double transgenic mice, no matter they were 
hyperactive or not.  
Neuron loss is a comparably late stage of neurodegeneration. Neuro-
inflammation such as astrogliosis was reported to be related to several 
neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, 
Huntington’s disease, and ALS (96). GFAP immuno-staining was used to 
determine whether there was astrocyte activation, an indicator of astrogliosis. 
Similar to non-tg control and non-hyperactive double transgenic, hyperactive 
double transgenic mice did not show signs of astrogliosis (Fig 2.7 B).  
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Fig 2.7 No neurodegeneration and neuron loss was detected in hyperactive 
double transgenic mice. Sections from non-transgenic (non-tg) control, non-
hyperactive double transgenic mice (dtg), and hyperactive double transgenic mice 
(dtg*) were stained with Nissl (A), and the quantification of neuron cells was shown 
in a bar graph (A). GFAP staining was performed in sections from non-tg, dtg and 
dtg* mice (B) to determine whether there was astrocyte activation. N=100 for each 
group in (A). N.S=not significant. Error bars indicate SEM.  
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Fig 2.7 No neurodegeneration and neuron loss was detected in hyperactive 
double transgenic mice. 
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2.4 Discussion 
TDP43 cytoplasmic inclusions and nuclear clearance are the two 
pathological events happening in most ALS patients (30, 91). A lot of efforts have 
been put to understand the normal functions of TDP43, and to determine the 
mechanism of TDP43 in ALS disease onset and development. Mouse is 
genetically closer to human than any other commonly studied animal models. 
Therefore, several TDP43 mouse models have been generated to study ALS 
mechanisms.  
TDP43 overexpression mouse models are comparably successful. Wild 
type TDP43 overexpression models were generated in several labs (70, 73). 
Although the results did not agree in every detail, consensus has emerged that 
homeostasis of TDP43 protein level is very critical to neuronal development in 
mouse (73). Overexpression of human wild type TDP43 in mice resulted in 
decrease of endogenous TDP43 expression level, the cytoplasmic aggregates 
formation, ubiquitylation and phosphorylation of cytoplasmic TDP43. What’s more, 
neurodegeneration and neuron loss were observed in those wild type TDP43 
overexpression mouse models as well (31). Overexpression of ALS-associated 
mutant TDP43 in mouse led to similar toxicity, at a more severe level (71, 88). 
These evidence supported the conclusion that a gain-of-toxicity mechanism 
contributed to the development of ALS.  
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However, the results mentioned above did not exclude the possibility that 
loss-of-function mechanism also played a role in ALS. Actually, the TDP43 
aggregates formed in those TDP43 overexpression mouse models could attract 
and sequester normal TDP43, thus causing a decrease in TDP43 function, leading 
to neurodegeneration and other consequences. To address the question whether 
loss-of-TDP43 function can cause, or at least contributes to, ALS, enormous efforts 
were put to generate TARDBP knock out mouse models. Because TARDBP is a 
developmental essential gene, TARDBP knockout mice were proved embryonic 
lethal (61-63). Even in conditional TARDBP knock out mouse model, where 
TARDBP was knock out after born, serious physiological defects were seen (60). 
Thus, a more sophisticated system in which TDP43 is moderately reduced in a 
controllable manner is badly needed. Therefore, we designed to make a Tet-
responsive conditional TARDBP knock down mouse model.  
The major advantage of conditional knock down system over conditional 
knock out system in general is that conditional knock down can be reversed, while 
knock out is a one way conversion.  Tet-on/tet-off systems are widely used to make 
conditional induction system. In this study, we put a miTDP43 containing intron 
into the 3’UTR of mCherry, and put the sequences as a whole under the control of 
Tet-responsive Ptight promoter. We used this sequence to generate a transgenic 
mouse, which, upon crossing with proper tTA lines, will drive mCherry expression 
and TARDBP knock down in a desired manner.  
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We used mPrp-tTA lines to cross with our TRE-mCherry-amiTDP43 mouse. 
Instead of inducing transgene expression in central nervous system, our system 
drove mCherry expression primarily in forebrain and cerebellum, but not in spinal 
cord. Because the development of paralysis requires lower motor neuron deficits, 
we did not expect the paralysis symptom in our mouse model. Instead, we 
observed a hyperactive phenotype in our double transgenic mice. This 
hyperactivity is very like transgene related. Hyperactivity was observed in all 3 lines 
we screened out of 108 founder lines and kept for further analysis. Of the 2 lines 
we did most of the experiment, 16.67% and 36.36% of double transgenic mice 
displayed hyperactivity respectively. But among the more than 3,000 mice I’ve 
checked and/or analyzed during screening and analysis process, only 1 mPrp-tTA 
mouse and 6 TRE-mCherry-amiTDP43 single transgenic mice  developed 
hyperactivity. Considering the false negative rate of genotyping, this incidence is 
really low. 
We measured miTDP43 expression level in double transgenic mice, and 
compared to that in single transgenic mice, and found that in double transgenic, 
miTDP43 was expressed 70 folds higher. Immuno-staining of TDP43 confirmed 
that TDP43 knock down was coupled with mCherry expression. Co-localization of 
mCherry with NeuN, a neuron cell marker, supported the conclusion that mCherry 
was induced in neurons. Lack of co-localization of mCherry with GFAP or IBA1 
indicated that mCherry was not expressed in astrocytes or microglia respectively.  
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To explore why some double transgenic mice developed hyperactivity while 
others did not, we compared TARDBP knock down level and neuron cell number 
in the two groups. No differences were found in terms of TARDBP knock down and 
neuron cell number in non-hyperactive double transgenic mice and hyperactive 
double transgenic mice. Instead, we did notice the difference in mCherry 
expression level in those two groups. Although no hyperactive phenotype was 
reported in currently available literature in which mCherry was expressed in central 
nervous system, we cannot exclude the possibility that the hyperactivity in our 
mouse model is actually caused by overexpression of mCherry.  
Due to the failure to induce mCherry expression and TARDBP knock down 
in spinal cord, we were unable to make a mouse model that recapitulates ALS 
symptoms. However, in our system, we restricted TARDBP knock down in 
forebrain neurons, and we did not see any obvious neurodegeneration, suggesting 
that neurodegeneration requires TARDBP knock down in other cell types, such as 
glia cells. Thus TDP43-associated neurodegeneration is probably cell-
autonomous.  
To make full use of our TRE-mCherry-amiTDP43 mouse model, we will 
keep searching for proper CNS tTA lines, in hopes of finding a line that can drive 
TARDBP knock down in both upper and lower motor neurons. In this way, we could 
get information to answer the question that whether loss of TDP43 function itself 
could lead to development ALS. Another interesting direction is to search for tTA 
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lines that could drive TRE controlled transgenes in astrocytes or microglia cells, so 
that we can address the problem whether loss of TDP43 function in those glia cells 
could act to cause TARDBP knock down in surrounding neurons and lead to 
neurodegeneraiton in the end.  
2.5 Material and methods 
TRE-mCherry-amiTDP43 construct making 
miRNA sequence targeting TARDBP as described before was cloned and inserted 
into the 3’UTR of mCherry gene. Then the whole sequence containing mCherry 
and the miRNA targeting TDP43 was cloned into pTRE-tight vector (Clonetech) 
with BamHI and EcoRV sites. The resulting plasmid was named TRE-mCherry-
amiTDP43.  
Cell culture, transfection and western blot 
NSC-34 cells were grown at 37°C in DMEM with 10% Tet-free FBS. The cells were 
then transfected with constructs using Lipofectamine 2000 according to 
manufacturer's recommendations (Invitrogen). After 24 hours of transfection, the 
cells were treated with or without doxycycline at the concentration of 50ng/mL for 
72 hours. Cells were collected at 400 g. The pellets were resuspended in RIPA 
buffer (0.1% SDS, 1% Nonidet P-40, 0.5% sodium dexoycholate, 5 mM EDTA, 150 
mM NaCl, 50 mM Tris-HCl, pH 8.0) plus protease inhibitors (Pierce). After clearing 
the lysate by centrifugation, protein concentration of cell lysates or tissue 
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homogenates was measured using BCA assay (Pierce, Rockford, IL). The 
samples were heated in Laemmli's buffer, and equal amounts of protein were 
loaded and resolved by SDS-PAGE. After transfer to nitrocellulose membranes, 
blots were blocked with 5% nonfat dry milk in PBST (0.25% Triton X-100 in PBS, 
pH 7.4) for 1 h, and then incubated with primary antibodies overnight. After 
washing 3 times in PBST, the membrane was incubated with anti-rabbit IgG (1
5000; Amersham Biosciences) or mouse IgG (1 5000; invitrogen) conjugated to 
horseradish peroxidase for 1 hour. Membranes were washed three times and 
proteins were visualized after ECL (Pierce) treatment and detected using the LAS-
3000 imaging system. The primary antibodies used were rabbit polyclonal anti-
TDP43 (1 1000; ProteinTech Group, Inc, Chicago, IL), anti-RFP (1:500, Abcam), 
and mouse monoclonal anti-α-tubulin (1 1000; Sigma). 
Transgenic mouse generating and maintenance 
TRE-mCherry-amiTDP43 was linearized with XhoI, and the fragment was 
submitted to transgenic mouse facility in UMass Medical School for micro-injection 
and founder line generation. The transgenic mice was made and maintained in a 
FVB/NJ background. All mouse experiments were approved by IACUC and 
conducted according to UMMS policies and procedures regulating the use of 
animals in research and the provisions of the PHS/NIH Guide for the Care and Use 
of Laboratory Animals. 
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Tail DNA was extracted as previously described(102) and genotyping was done 
by PCR using the following primers: mCherry, 5’-AAGGGCGAGGAGGATAACAT-
3’, 5’-CCCATGGTCTTCTTCTGCAT-3’; tTA: 5’-CGC TGT GGG GCA TTT TAC 
TTT AG-3’, 5’-CAT GTC CAG ATC GAA ATC GTC-3’.  
Histological processing and immunostaining 
Mice were transcardially perfused with ice-chilled PBS followed by cold fixation 
buffer containing 4% paraformaldehyde and 0.1% of glutaraldehyde in PBS. 
Tissues were post-fixed by soaking in the same fixative for 48 h. Brain and spinal 
cord and other tissues from fixed mice were cryoprotected in 30% sucrose for 24–
48 h. Tissues were then embedded in OCT compound and frozen sectioned using 
a cryostat. For immunofluorescent staining, the sections were washed in 1% Triton 
X-100 in PBS for 30 min and with PBS for 2 min, and then blocked in 10% serum 
with 0.05% Triton X-100 and 0.05% Tween 20 for 30 min at room temperature. 
Primary antibodies were added to the sections and incubated at 4°C overnight. 
The sources of primary antibodies and dilutions are as follows: TDP43 (1 1000; 
ProteinTech Group, Inc, Chicago, IL), NeuN (Millipore MAB377, 1:200), GFAP 
(Abcam Ab7260, 1:1000), IBA1 (BioCare Medical CP290A, B, 1:200), and RFP 
(Abcam, 1: 500). Following the incubation, sections were washed three times for 
5 min each, incubated in the appropriate secondary antibody at room temperature 
for 90 min, washed three times in PBS for 5 min each, mounted with Vectashield 
Mounting solution and sealed with nail polish. Images of the brain and spinal cord 
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sections were taken with a Nikon Eclipse Ti Widefield fluorescence microscope 
equipped with a Retiga-2000RV cooled-CCD camera. 
For immunohistochemistry, sections were washed three times in PBS containing 
0.25% Tween 20 and then stained following the manufacturer's instructions for 
Vectastain ABC kit, Elite PK-6100 standard ImmPact tm DAB peroxidase 
Substrate kit SK-4105 (Vector Lab). The sections were then mounted on slides 
and dried overnight at 55°C. After soaking in Xylene two times for 2 min each, the 
slides were sealed with Permount (Vector Lab). 
Statistical analyses 
Travel time, feeding time, vertical movement time, and exploratory time were 
obtained from individual animals. ami-TDP43 expression level were determined in 
double transgenic mice and single transgenic mice. mCherry and TDP43 
fluorescence strength were determined in each single cell. The averages and 
standard deviations were calculated for each group. Statistical comparisons were 
done using Student’s t-test. 
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Chapter III 
Gudu, an Armadillo repeat-containing 
protein, is required for spermatogenesis in 
Drosophila 
The work described in this chapter has been published (Cheng W, Ip YT, Xu Z. 
Gene. 2013 Dec 1;531(2):294-300.) 
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3.1 Abstract 
The Drosophila annotated gene CG5155 encodes a protein that contains 
10 Armadillo-repeats and has an unknown function. To fill this gap, we performed 
loss-of-function studies using RNAi. By analysis of four independent Drosophila 
RNAi lines targeting two non-overlapping regions of the CG5155 transcript, we 
demonstrate that this gene is required for male fertility. Therefore, we have named 
this gene Gudu. The transcript of Gudu is highly enriched in adult testes. 
Knockdown of Gudu by a ubiquitous driver leads to defects in the formation of the 
individualization complex that is required for spermatid maturation, thereby 
impairing spermatogenesis. Furthermore, testis-specific knockdown of Gudu by 
crossing the RNAi lines with Bam-Gal4 driver is sufficient to cause the infertility 
and defective spermatogenesis. Since Gudu is highly homologous to vertebrate 
ARMC4, also an Armadillo-repeat-containing protein enriched in testes, our results 
suggest that Gudu and ARMC4 is a subfamily of Armadillo-repeat containing 
proteins with an evolutionarily conserved function in spermatogenesis. 
 
3.2 Introduction 
The study of conserved protein domains often provides important insights 
into the function and evolution of gene and protein families. Armadillo-repeat 
(ARM-repeat) motif was first identified in the Drosophila melanogaster β-catenin 
ortholog Armadillo (103, 104). Each ARM-repeat is ~42 amino acids long and the 
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number of repeats in different proteins is highly variable, ranging from 3 to 60. 
Structural analysis reveals that an ARM-repeat is composed of three α-helices. 
The tandem ARM-repeat units fold as a superhelix, providing a platform for 
interaction with other protein partners (104-109). 
 Even though highly divergent ARM-repeat sequences share 
structural similarity, it is sometimes difficult to define cross-species orthologs and 
conserved biological functions based on the ARM-repeat sequences alone due to 
the degeneration of the sequences among the members of this protein family. 
Therefore, we initiated the functional study of a Drosophila ARM-repeat containing 
(ARMC) protein, annotated as CG5155 in the Drosophila genome. Knockdown of 
this gene transcript, either ubiquitously or specifically in testis, caused male sterility. 
Therefore we have named this ARMC protein Gudu (Chinese, meaning alone 
without progenies). 
 In animals, spermatogenesis is a conserved process that produces 
mature haploid sperms capable of fertilizing oocytes (110). Spermatogenesis 
involves a series of tightly regulated stages including mitotic proliferation, meiotic 
division, and cellular remodeling (111). The adult Drosophila testis is a bipolar 
tube-like structure. At the apical end of the tube, germline stem cells divide to 
produce spermatogonial cells, which go through mitotic and meiotic divisions to 
yield a group of 64 inter-connected early spermatids. The spermatids differentiate 
into the characteristic elongated shape and separate from each other through a 
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process known as individualization to form mature sperms, which move into the 
seminal vesicle through the open basal end (112). 
 Many of the classic male sterile mutant strains show spermatid 
individualization failure, a defect observable by phase contrast microscopy (113). 
Individualization initiates when the F-actin based individualization complex (IC), 
composed of 64 actin cones, assembles around each spermatid nucleus and 
moves synchronously down the length of the cyst toward the tails, expelling the 
excess cytosol and simultaneously wrapping each spermatid into its own plasma 
membrane (114). Defects in IC formation and movement can lead to failure of 
individualization, resulting in sperm reduction and male sterility (111, 114). 
Previous studies have identified many genes involved in individualization such as 
those coding for auxilin, myosin VI, clathrin, Rab11 and Lump (111, 115). These 
proteins either are part of the IC or regulate the integrity and membrane trafficking 
of the IC.  
 Using RNAi targeting the Gudu transcript, we show that loss of Gudu 
function leads to male, but not female, sterility. Moreover, Gudu RNAi flies 
displayed irregular IC morphology in their testes and drastically reduced number 
of mature sperms in their seminal vesicles. These results demonstrate that Gudu 
is essential for male fertility in Drosophila and suggest that Gudu plays a crucial 
role in spermatogenesis, particularly in the individualization process. Since 
ARMC4 is the closest mammalian homolog of Gudu and is also highly expressed 
in the mouse testes, our data suggests that ARMC4 may have a conserved 
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function in sperm individualization and male fertility in mammalian species 
including humans. 
3.3 Results 
3.3.1 CG5155 contains Armadillo-repeats and is highly enriched in adult 
testes  
Other than the founding member β-catenin and the importins, most other 
ARMC proteins in the annotated Drosophila genome have not been characterized. 
CG5155 is a gene encoding an ARMC protein with 669 amino acids containing ten 
ARM-repeats (Fig. 3.1A) (116). Based on sequence similarity, this gene also has 
homologs in other metazoans including humans (Fig. S1). A functional study of 
this gene in Drosophila therefore may shed light on whether this subfamily has a 
conserved function. The first hint for a function of CG5155 is the observation that 
the transcript levels were much higher in adult male flies than females (Fig. 3.1B). 
This differential expression suggested that CG5155 might be expressed in a male 
specific organ. This was confirmed by a measurement of the mRNA level in testes, 
which showed a ~6 fold enrichment over the whole male fly (Fig.3.1C). 
Furthermore, in male carcasses that did not contain testes, the CG5155 mRNA 
level was ~10 fold lower compared to those with testes (Fig. 3.1C). Thus, CG5155 
has a highly testis-enriched expression pattern. 
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3.3.2 Knockdown of CG5155 causes male infertility 
To investigate the function of CG5155, we utilized four different transgenic 
strains that harbor constructs to express double stranded (ds) RNA that target 
three different regions of CG5155 (Fig. 3.1A). The expression is under the control 
of UAS promoter, and therefore, can be driven by Gal4 expressed in various 
tissues or developmental stages. While the RNAi-1, 2 and 3 lines targeted 
overlapping regions of CG5155 mRNA, the RNAi-4 line targeted a region that does 
not overlap with the other targets (Fig. 3.1A). When the UAS-dsRNA strains were 
crossed with the ubiquitous tubulin-Gal4 driver, CG5155 mRNA levels, as assayed 
by RT-PCR, were reduced by 80-90% in male progenies of all four strains (Fig. 
3.1D). The survival time of adult progenies carrying the driver and the dsRNA 
constructs was similar to that of the controls, suggesting that this knockdown or 
the loss of function of CG5155 did not affect the viability of the animals. Meanwhile, 
the lower level of expression in female flies was further reduced by ~80% after 
RNAi (Fig. 3.1E). This suggests that CG5155 is also expressed at low levels in 
tissues other than the testes. 
 Because CG5155 is highly enriched in testes, we examined whether a 
partial loss of CG5155 expression affected testes-related functions such as fertility. 
Wild type females crossed with CG5155 knockdown males laid similar number of 
eggs as the ones crossed with the wild type males (Table 3.1). However, almost 
all the embryos derived from CG5155 knockdown males failed to hatch (Table 3.1). 
In contrast, when the CG5155 knockdown females were crossed with wild type 
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males, both the number of embryos laid and the hatching rate were not affected 
(Table 3.1). Therefore, CG5155 knockdown caused compromised male fertility but 
not female fertility. Because of the testes-enriched expression and the loss-of-
function phenotype of male sterility, we have named CG5155 Gudu.  
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Fig. 3.1. CG5155/Gudu expression pattern and knockdown. 
 (A) Schematic representation of CG5155/Gudu, which encodes a protein with 669 
amino acids. The blue boxes indicate 10 predicted ARM repeats based on 
sequence similarity. The four RNAi lines targeting 3 different regions of the gene 
are illustrated: RNAi lines 1 and 2 are independent transgenic lines of the same 
construct with insertions located on chromosome 2 and 3, respectively. (B) By 
qPCR, male flies express ~10 times more CG5155/Gudu mRNA than the female 
flies. (C) The CG5155/Gudu mRNA is highly enriched in fly testis. Total mRNA was 
extracted from the whole male flies, dissected testes, and the carcasses excluding 
the testes. The CG5155/Gudu mRNA levels were measured using qPCR. A 
greater than 95% of CG5155/Gudu transcript in male flies is present in testes. The 
relative mRNA expression of CG5155/Gudu based on qPCR of RNA isolated from 
(D) whole male and (E) female flies. All 4 RNAi lines knocked down the expression 
of Gudu to ~15% or lower of the level in wild type males and to ~25% or lower of 
the level in wild type females. Note that the overall levels in female flies were ~10 
times lower than that in male flies as shown in Fig. 1B, although the levels were 
set to 1 in both control flies in 1D and 1E. 
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Fig. 3.1. CG5155/Gudu expression pattern and knockdown 
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Table 3.1. Infertility in Gudu knockdown males. 
The mRNA expression level was measured by quantitative rtPCR using mRNA 
extracted from whole flies. The expression levels in wild type male or female were 
each set as 100% and the expression levels of the same sex flies from the RNAi 
lines were compared. For fertility test, 5 males from each RNAi line were crossed 
with 10 wild type females. The embryos laid by the 10 females were counted for 
the first 5 consecutive days and the percentage of hatched embryos determined 
on the next day. To test the female fertility, 10 Gudu knockdown females were 
crossed with 5 wild type males from each RNAi line and the embryos laid and 
hatching rate were determined. 
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Table 3.1. Infertility in Gudu knockdown males 
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3.3.3 Gudu knockdown caused abnormal sperms after meiosis 
 The normal number of eggs laid by the Gudu knockdown male-crossed wild 
type females described above suggested that the mating behavior was normal in 
the knockdown males. We hypothesized that the male fertility defect was caused 
by abnormality in one of the steps in spermatogenesis. To investigate this 
possibility, we examined squash preparation of testes from wild type and the RNAi 
males. Spermatids at onion stage in Gudu RNAi lines contained white nuclei and 
associated dark mitochondria nebenkern in a 1:1 ratio (Fig. 3.2B-E), the same as 
control (Fig. 3.2A). Furthermore, the testes in the knockdown fly contained 
elongated spermatids (Fig. 3.3), suggesting that the germline cell division, as well 
as spermatogonial cell mitotic and meiotic divisions are largely normal. However, 
the testes in the RNAi fly contained spermatid bundles with little mobility (Fig. 3.3B; 
personal observation), whereas wild type testes contained motile and 
individualized sperms (Fig. 3.3A). This kind of abnormalities was observed in all 
the Gudu knockdown lines.  
 The protein Don Juan is expressed in sperm tails. Thus the line dj-GFP, 
which was generated by placing GFP under control of the Don Juan promoter, can 
be used to illuminate the late elongation-stage spermatids (117). We crossed dj-
GFP with flies containing both Gudu RNAi construct and tub-Gal4, or with wild type 
flies as control, and then examined whether sperms were successfully made and 
stored in seminal vesicles. While wild type seminal vesicles showed abundant 
mature individual sperms (Fig. 3.3C-C’’), seminal vesicles from Gudu RNAi lines 
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only contained few GFP-illuminated sperms and conspicuous bundled spermatids 
(Fig. 3.3D-E’’). These results suggest that knockdown of Gudu expression leads 
to a post-meiotic defect, perhaps at a differentiation stage prior to sperm 
maturation and movement to seminal vesicles.  
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Fig. 3.2. The defect of sperm maturation was post-meiotic after Gudu RNAi.         
Panels A to E are phase contrast images of squashed testes from male flies with 
the indicated genotypes. All the wild type and RNAi lines contained normal onion-
stage spermatocytes. The 1:1 ratio of the white nucleus and the associated dark 
mitochondria nebenkern (arrowheads) was retained in all the RNAi lines, 
suggesting that the spermatogenesis process is normal up to this stage. Scale bar: 
A-E, 10µm 
 
 
 
 
 
 
 
 
 
 
 
77 
 
Fig. 3.2. The defect of sperm maturation was post-meiotic after Gudu RNAi.          
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Fig. 3.3. Gudu knockdown caused sperm maturation defects.  
Panels A and B are phase contrast images of elongated individual sperms from 
testes of a 2 day-old WT male (A) and bundled spermatids from a 2 day-old Gudu 
RNAi male (B). Note the smooth texture of individual sperm released from the 
squashed WT testis. In contrast, there was frequent bundling of sperms in testes 
of the RNAi males. Panels C to E’’ are DAPI and rhodamine-conjugated phalloidin 
stained seminal vesicles of WT and Gudu RNAi lines, where the GFP tagged Don 
Juan protein was expressed to illustrate sperm tails. In C, abundant loose 
individual sperms were seen in seminal vesicle from WT male fly. In D and E, the 
seminal vesicles from RNAi-1 and RNAi-4 lines contained very few sperms. Scale 
bars in A and B, 10 µm; C-C’’, 100 µm; D-E’’, 50 µm. Green is dj-GFP, red is 
phalloidin, and blue is DAPI. 
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Fig. 3.3. Gudu knockdown caused sperm maturation defects 
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3.3.4 Knockdown of Gudu results in defective individualization complexes in 
testes 
An important step of sperm maturation is the individualization of the bundled 
spermatids. This process is controlled initially by the IC that contains actin cones 
surrounding the spermatid heads. Therefore, we visualized the ICs by staining the 
testes with fluorescent phalloidin that binds actin. Different from the well-organized 
morphology seen in wild type testes (Fig. 3.4A’, arrow head), the ICs in the Gudu 
RNAi testes (Fig. 3.4B’ and C’, arrow heads) stained poorly, and were more 
disorganized and diffused. In addition, the spermatids around IC (illuminated by 
Don Juan-GFP) were poorly visualized (Fig. 3.4B'' and C''), in sharp contrast with 
the clear spindle structure in wild type (Fig.3. 4A). DAPI staining for spermatid head 
DNA was detectable around the IC (Fig. 3.4C’’), suggesting that the IC around the 
spermatid heads can be initiated but the defect develops around the time of IC 
formation and movement down the spermatid tail. These results suggest that loss 
of Gudu function leads to defects in spermatid individualization, which in turn 
reduces normal sperm production and causes low fertility in the male flies.  
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Fig. 3.4.  Knockdown of Gudu disrupts the individualization complex (IC). 
Rhodamine-conjugated phalloidin stained actin, the major component of IC. DAPI 
was used to stain the nuclear DNA. GFP-tagged Don Juan protein illuminated 
spermatids. Wild type testes show highly organized ICs as a result of coordinated 
movement of actin cones. All 64 actin cones in each bundle are located tightly 
together (A’, arrow head). Knockdown of Gudu led to diffused and disorganized 
ICs (B’ and C’, arrow head). The organized ICs were missing or only very few left 
in the RNAi lines. Scale bar: 40 µm. Green is dj-GFP, red is phalloidin, and blue is 
DAPI.  
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Fig. 3.4.  Knockdown of Gudu disrupts the individualization complex (IC). 
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3.3.5 Specific knockdown of Gudu in testes causes infertility in male flies 
 The male infertility resulted from the ubiquitous Gudu knockdown left the 
possibility that the defects might be caused in part or entirely by problems in non-
testes tissues. To test this, we used Bam-Gal4 driver line, which has been shown 
to drive ectopic protein expression in early-mid spermatocytes and sometimes in 
late-elongation stage spermatids (118). Crossing Bam-Gal4 with RNAi-2 line 
successfully knocked down Gudu to ~10% of the wild type mRNA level (Table 3.1). 
Consistent with the ubiquitous knockdown results, testes-specific knockdown of 
Gudu also led to male sterility (Table 3.1). Furthermore, analysis of Bam-Gal4; 
GuduRNAi-2 male testes confirmed that the spermatids were bundled rather than 
individualized (Fig.3.5B, arrowhead) and the ICs were disorganized (Fig. 3.5C, 
arrow head), while the 1:1 ratio of white nuclei and associated dark mitochondria 
nebenkern during onion stage was maintained (Fig. 3.5A, arrow head). These 
results confirm the hypothesis that the function of Gudu gene is critical to spermatid 
individualization and a loss of Gudu function in testes is sufficient to cause male 
sterility. 
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Fig. 3.5. Abnormalities in the testes of the male flies generated from 
crossing Bam-Gal4 males with Gudu RNAi-2 females generated male flies.  
A and B are phase contrast images of testes squash showing testis-specific 
knockdown of Gudu causes spematids individualization defects (B, arrowhead). 
The defects appeared after meiosis because the characteristic 1:1 ratio of white 
nucleus and associated dark mitochondria nebenkern is retained (A, arrowhead). 
Rhodamin-conjugated phalloidin staining of F-actin revealed the disorganized IC 
(C, arrowhead). Scale bar: A and B, 10 µm; C, 40 µm.  
. 
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Fig. 3.5. Abnormalities in the testes of the male flies generated from 
crossing Bam-Gal4 males with Gudu RNAi-2 females generated male flies.  
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3.3.6 Gudu homolog ARMC4 is enriched in mammalian testes 
 As shown in Fig. S1, Gudu is highly homologous to vertebrate ARMC4 
protein family. To explore whether AMRC4 plays similar functions, we measured 
the mRNA levels of ARMC4 in various mouse tissues. We found that ARMC4 
transcript was also highly enriched in mouse testes compared to the other tissues 
(Fig. 3.6). This result suggests that ARMC4 may perform a similar function in 
mammalian spermatogenesis. Further experiments will be necessary to confirm 
this function in mammals. 
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Fig. 3.6. ARMC4 is highly enriched in mouse testes.  
ARMC4 mRNA level in various mouse tissues was determined by quantitative PCR 
using 5S rRNA as internal control. The ARMC4 transcript is highly enriched in 
mouse testes, with very little expression in other tissues, similar to the pattern of 
Gudu in flies. **, p<0.01. Error bars indicate SD.  
  
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
 
Fig. 3.6. ARMC4 is highly enriched in mouse testes.  
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Fig. S1 The closest homolog of Gudu based on sequence similarity is 
ARMC4 (http://pfam.sanger.ac.uk).  
These ARMC4 homologs in human, mouse, chicken, frog and fly constitute a 
subfamily of ARM-repeat-containing proteins. Sequence alignment of this 
subfamily was done using the online software at 
http://www.ibi.vu.nl/programs/pralinewww/. ARMC4 is highly conserved in 
vertebrates. The tandem ARM repeats are in the C-terminus. The similarities 
between human and mouse, human and chicken, and human and frog ARMC4 are 
91%, 77% and 79%, respectively. While the vertebrate proteins are approximately 
1110 a.a., Gudu is only 669 a.a. long, missing the N-terminal counterpart of 
vertebrate Nonetheless, the whole Gudu protein sequence matches the a.a. 434 
to the C-terminal end of vertebrate ARMC4. Both vertebrate ARMC4 and fly GUDU 
contain 10 ARM repeats. 
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Fig. S1 The closest homolog of Gudu based on sequence similarity is 
ARMC4 (http://pfam.sanger.ac.uk).  
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3.4 Discussion 
Our experiments have unveiled an essential function of Gudu/CG5155, a 
predicted ARMC protein in Drosophila, in male fertility. Gudu expression is highly 
enriched in Drosophila testes. Reduced expression of Gudu in four RNAi lines 
caused male infertility, but did not affect female fertility. Additionally, testis-specific 
knockdown of Gudu leads to the same infertility in males. By phase contrast and 
fluorescence microscopy, we observed a normal one-to-one nuclei-to-
mitochondria nebenkern ratio at the onion stage in the Gudu knockdown flies, 
suggesting that the spermatogenesis went normally up to the meiosis. On the other 
hand, we observed conspicuous abnormalities in the ICs, which strongly suggest 
that the individualization process is disrupted. Such a disruption is expected to 
impair spermatogenesis and result in few normal sperms. Indeed, we observed 
much reduced mature individual sperms in the seminal vesicles of the Gudu 
knockdown flies. These observations demonstrate that Gudu function is required 
in spermatogenesis, and furthermore, suggest that Gudu plays a critical role in the 
individualization process during spermatogenesis.  
 Individualization has been extensively studied in Drosophila and many 
genes are involved in this process, including lump, myosinVI, auxilin and npc1 (111, 
115, 119, 120). From these studies, actin assembly, apoptosis and membrane 
trafficking become the three best understood processes shown to affect different 
aspects of sperm maturation. Because the IC is made of 64 actin cones, any defect 
in the IC formation, actin dynamics, and maintenance of IC integrity could lead to 
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individualization failure and ultimately male infertility (121-124). Because ARMC 
proteins likely function as scaffolds for multi-protein complexes (106), Gudu may 
function as an interacting partner for some of the proteins involved in the 
individualization process.  
 System analysis revealed that almost half of the genes in the Drosophila 
genome are expressed in testis, approximately 25% are testis-enriched and 10% 
(~1500 genes) contribute to male fertility (125-128). Our work demonstrates that 
Gudu expression is highly enriched in testis and functions in male fertility. Gudu 
mRNA has a 10-fold lower expression in females, and knocking down Gudu by a 
ubiquitous driver did not affect female fertility. Furthermore, the four RNAi lines we 
used brought down Gudu mRNA to ~10% of the wild type level, yet the flies were 
viable and showed no detectable mating or behavioral defects. These results 
suggest that Gudu mainly functions in testis and is indispensable for 
spermatogenesis. 
 These findings raise interesting implications for the function of Gudu’s 
mammalian homolog AMRC4. The shared sequence-homology (Fig. S1) and 
testis-enriched expression pattern between Gudu and AMRC4 (Fig. 1 and 6) 
suggest that ARMC4 plays a similar role in mammalian testes. Worldwide, male 
infertility claims an estimated 5% victims in human male population and defects in 
sperm production is a common cause for this problem (129). Therefore, further 
studies on the role of Gudu and ARMC4 in spermatogenesis will help to 
understand male infertility.  
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3.5 Materials and Methods 
Fly strains and RNAi knockdown of Gudu 
 Information on Drosophila genes and stocks can be found in Flybase 
(http://flybase.org). w1118 was used as wild type controls. Gudu RNAi-1, RNAi-2, 
RNAi-3 (#27364, #27365, #106963) were obtained from Vienna Drosophila RNAi 
Center. Gudu RNAi-4 (#31568) as well as dj-GFP (#5417) was obtained from 
Bloomington stock center. tubulin-Gal4 was used to drive the ubiquitous 
expression of the double-stranded RNA (dsRNA) under the control of UAS. Testis 
specific Bam-Gal4 was a kind gift from Dr. Xin Chen (Johns Hopkins University). 
Stocks were kept on cornmeal-yeast-molasses-agar media at room temperature.  
 
Fertility assay 
 To examine the male fertility, five 4-day old Gudu RNAi males from each 
line were mated with 10 virgin w1118 females. The flies were transferred to a new 
vial every day, leaving the embryos on the food. The embryos laid were counted 
and the hatching rate was determined by dividing the number of viable moving 
larvae the next day by the number of embryos laid. The embryos were counted for 
five consecutive days, and the hatching rate determined subsequently. For female 
fertility, 10 virgin Gudu RNAi females from each line were crossed with five 4-day 
old w1118 males. The number of embryos and hatching rate were determined as 
described above. 
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 Testes phenotypic analyses 
 Testes of 4-day-old males were dissected out in 1XPBS buffer. For squash, 
dissected testes were transferred to a small drop of PBS on a microscope slide 
and gently pushed under the weight of the cover slip to release the testes content. 
The testes were observed under phase contrast settings on a Nikon Eclipse Ti 
microscope. To visualize the seminal vesicles and the individualization complexes, 
the dissected testes were fixed in medium containing PBS and 4% formaldehyde 
(Mallinckrodt Chemicals) for 2 hours, and washed in PBS plus 0.1% triton-X-100. 
The tissues were incubated in rhodamine-conjugated phalloidin (1:500, Sigma, 
USA) for 1 hour at room temperature and mounted in Vectorshield with DAPI 
(Vector Laboratories, CA). The dj-GFP was visualized in formaldehyde fixed 
tissues. The testes were examined and photographed using a Nikon Eclipse Ti 
fluorescence microscope. 
 
Quantitative PCR 
 RNA was extracted from the whole fly body or dissected testes from 
approximately 3 days old adult flies (control w1118 and 4 RNAi lines as listed 
above crossed with tubulin-Gal4) using TRIzol Reagent (Invitrogen). Mouse tissue 
collection and total mRNA preparation was performed as described previously 
(115). The integrity of RNA was analyzed by spectrophotomety and agarose 
electrophoresis. The RNA was treated with DNase I to remove the contaminating 
genomic DNA. cDNA was synthesized from 500ng total RNA using SuperScript III 
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Reverse Transcriptase (Invitrogen). iQ SYBR Green Supermix (Bio Rad) was used 
to carry out the quantitative real time PCR in a  C1000 Thermal Cycler (Bio Rad). 
rp49 expression was used as an internal control to normalize Gudu mRNA 
expression in flies. 5s rRNA expression was used as an internal control to 
normalize ARMC4 mRNA expression in mouse. The following primers were used 
at a concentration of 500nM: Drosophila Gudu primers 5’-CAT CGA CAT CAA GTT 
GAG CAT T-3’ (forward) and 5’-AAG GAG CTG AGG CAT CAA AG-3’ (reverse); 
Drosophila rp49 primers 5’-CGG ATG GAT ATG CTA AGC TGT-3’ (forward) and 
5’-GCG CTT GTT CGA TCC GTA-3’ (reverse); mouse ARMC4 primers 5’-CAT 
TCC AGT GGT GGG GAC AT-3’ (forward) and 5’-ACC AGG TCT CGG GTC TCC 
TC-3’ (reverse); mouse 5s rRNA primers 5’-CTC CAT CCT CAT CCA ACA CC-3’ 
(forward) and 5’-GGA GGG GCA AGA TAC ACA GA-3’ (reverse).  
Statistical analyses 
Statistical differences were analyzed by Student’s t-test for two group comparisons. 
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Chapter IV 
Final summary and discussion 
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In my Ph.D thesis, I dedicated on exploring the function of ALS related 
genes and investigating mechanisms of these genes to cause ALS.  In the first 
part, I applied RNAi approaches and tet-on/tet-off system to make a conditional 
TARDBP knock down mouse model. It was designed as a bipartisan system. To 
knock down TDP43, we need to cross the line with miRNA under tet-responsive 
control with another line that expresses tTA in a spatial or temporal specific manner. 
I successfully made the tet-responsive miRNA mouse line, and crossed it with an 
mPrp-tTA line. Multiple lines of evidence demonstrated that TDP43 was knocked 
down in cells where transgene was induced. However, this mPrp-tTA line failed to 
drive transgene expression in spinal cord in this case. Since neurodegeneration is 
usually observed in lower motor neurons from spinal cord and abnormalities of 
TDP43 in lower motor neurons was required to recapitulate ALS phenotype, we 
didn’t get ALS phonotype from current crossing. Nevertheless, our data suggested 
that knocking down TARDBP in forebrain neurons only was not sufficient to cause 
neurodegeneration. It’s likely that TARDBP in astrocytes and microglia cells also 
play an important role in cell survival in CNS.   
In the second part, I made a pioneer effort to study the function of ARMC4 
and its association with ALS. We decided to start with a possible ARMC4 homolog 
in Drosophila, CG5155, due to the easiness to genetically manipulate fly genes 
and the short life circle of drosophila as a model organism. Although ARMC4 was 
determined not an ALS causative gene according to further clinical and genetics 
analysis, we did report for the first time the function associated with CG5155. We 
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found that CG5155 was highly enriched in fly testis, and the product of CG51555 
is important for spermatid individualization complex formation and movement. 
Thus, knocking down CG5155 in the whole body or specifically in testis led to 
defects in spermatogenesis, and ultimately infertility in male flies. Therefore, we 
named CG5155 Gudu (Chinese, meaning alone without progenies).  
Does loss of normal TDP43 function contribute to neurodegeneration and 
ALS development? 
Central in the research about TDP43 is to determine which mechanism 
contributes to ALS development. Is it gain of toxicity or loss of function? Currently 
available mouse models lean towards gain of toxicity (67-70, 77). However, there 
are some results pointing to loss of function mechanism. Knocking down TARDBP 
in neuron cell culture resulted in cell morphology disruption and cell death (94). 
Gene expression in CNS was also largely altered if TARDBP was knocked down. 
The ultimate demonstration of TDP43 loss of function mechanism would be a 
TDP43 dysfunction mouse model. The major obstacle to this direction is that 
TARDBP is a developmental essential gene so that TARDBP knock out causes 
embryonic lethality in mouse, and even conditional knock out of TARDBP in 
adulthood led to rapid loss of body fat and lethality in mouse (60-63).  
In our conditional knock down strategy, we applied RNAi approaches to 
decrease the expression level of TDP43, because knock down is a method to 
reduce gene expression, but never completely depletes a gene. It probably 
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explains why our double transgenic mice could escape embryonic lethality and be 
born. The absence of mCherry in spinal cord seem to be the problem caused by 
mPrp-tTA line, although the reason why mPrp-tTA did not induce transgene 
expression in an expected manner is unclear. We detected amiRNA expression to 
be 70-fold higher in TRE-mCherry-amiTDP43/mPrp-tTA double transgenic mice 
compared to TRE-mCherry-amiTDP43 single transgenic mice. It is in line with our 
previous finding that include artificial miRNA in introns and put the whole structure 
in the 3’UTR of a fluorescent reporter gene did not alter the expression of miRNA, 
but enhanced the expression of the fluorescent protein. In our system, mCherry 
served as a useful indicator for screening and analysis. The mCherry fluorescence 
was so strong that its expression in tail and ear could be seen with naked eyes. In 
my TARDBP knock down mouse model, mCherry, the indicator of amiTDP43 
expression, was only induced in cortex neurons, but not in astrocytes or microglia 
cells. In a constitutive TARDBP knock down mouse model generated in our lab 
(submitted data), TARDBP knock down was achieved in all the three cell types in 
CNS. Neurodegeneration as well as neuron loss was observed in those mice. 
Combined the two sets of data, it’s persuasive that the function of TDP43 is 
important in neurons and glia cells in terms of cell survival.   
Many more experiment can be designed and carried out based on the TRE-
mCherry-amiTDP43 mouse. The most urgent is to find a tTA line that can reliably 
induce mCherry expression and TARDBP knock down in CNS. Once we can get 
TARDBP knock down in both upper and lower motor neurons, we can get a 
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definitive answer to the question as whether knocking down TARDBP in neurons 
can cause neurodegeneration and ALS, e.g., whether neurodegeneration 
associated with TDP43 loss-of-function is cell-autonomous or not. To further 
address this question, it is intriguing to use astrocyte and/or microglia specific tTA 
lines to drive TDP43 knock down in those glia cells. Since it’s been reported that 
introducing TDP43 mutations into astrocyte caused non-cell-autonomous neuron 
death in rats, it’s reasonable to hypothesize that disrupt TDP43 normal function by 
knocking down TARDBP in astrocyte will probably cause similar consequences. 
To test this hypothesis, astrocyte specific knock down TARDBP mouse model is 
the most direct method.  
Our conditional TARDBP knock down system in mouse model is a very 
useful tool to study TDP43 normal function, and point the direction for therapeutic 
strategies to cure ALS.  
Neurodegeneration to infertility: exploring the function of ARMC4 
The ARMC4 project in my Ph.D thesis serves as a perfect example on the 
uncertainty of science. And it is this uncertainty that holds the beauty and charm 
of science exploration.  
We started AMRC4 project because ARMC4 was originally isolated from an 
Israel ALS family as a possible ALS causative gene. Little was known about this 
Armadillo domain containing protein, and the resources were very limited. After 
careful alignment, we found that CG5155 in drosophila was highly possible to be 
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a homolog to ARMC4 in mammals, because the two genes share 91% similarity in 
amino acid sequences. Due to the easiness to manipulate genes in drosophila and 
the comparably short life cycle and experimental time line in Drosophila, we 
decided to start with CG5155 in fly and then went back to mouse ARMC4.  
Our initial plan was to use RNAi to knock down CG5155 in the whole fly 
body, and we expected to see some neuronal phenotype, such as locomotion 
defects. However, although we achieved robust CG5155 knock down in 3 RNAi 
lines (Fig 3.1 B and C), we did not observe any obvious neuronal phenotype. 
Instead, I noticed that the male progeny in which CG5155 was knocked down was 
infertile. This finding led me to check the expression pattern of CG5155. Because 
there was no CG5155 antibody available, we had to use quantitative real-time PCR. 
The results showed that CG5155 mRNA transcript was extremely highly-enriched 
in fly testis (Fig D and E). The testis enrichment of CG5155 expression and the 
male infertility caused by loss of CG5155 suggested that CG5155 was probably 
involved in spermatogenesis.  
A series of testis morphology study was carried out and abnormality of 
sperms in CG5155 knock down flies was detected. Step-by-step analysis of 
spermatogenesis nailed CG5155 down to the final stage of spermatogenesis: 
individualization. Phalloidin staining of F-actin, the major component of 
individualization complex (IC), combined with visualized spermatids in dj-GFP flies, 
clearly demonstrated that CG5155 was required for IC formation and proper 
movement. We confirmed the result by crossing the 4 RNAi lines with a testis-
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specific Gal-4 driver. Thus, we named the gene Gudu (Chinese, meaning alone 
without progenies). 
We then got back to our starting point, and check the expression pattern of 
ARMC4 in mice with quantitative real-time PCR. Consistent with its similarity to 
Gudu in amino acid sequence, ARMC4 was also highly enriched in mouse testis, 
suggesting a similar function of ARMC4 in mouse male fertility. 
Later on, further clinical and genetics analysis of that Israel ALS family 
excluded ARMC4 as an ALS causative gene. Recently, mutations in ARMC4 were 
reported to be associated with primary ciliary dyskinesia (PCD) (130). People have 
been speculating the role of ARMC4 in sperm development, but no experiment 
result was reported. Our data on Gudu, a possible Drosophila homolog to ARMC4, 
provided an indication of the function of ARMC4 in fertility.  
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